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Abstract 
The major challenge in anti-melanoma therapy is the tremendous plasticity of melanoma 
cells that leads to acquisition of resistance mechanisms and ultimately, to treatment failure 
and death. An emerging concept of melanoma cell plasticity is the so-called phenotype 
switch that describes the conversion of highly proliferative and little invasive into less 
proliferative and highly invasive melanoma cells. In vitro models of this phenotype switch are 
needed to understand the molecular mechanisms that drive cellular plasticity. Here, I 
demonstrate that abortion of reprogramming towards pluripotency converts HCmel17 
melanoma cells into slowly proliferating cells with substantially elevated invasive potential. In 
detail, I show that reprogramming of murine melanoma cells is a stable process that induces 
gene expression changes in a time-dependent manner. Partially reprogrammed cells exhibit 
elevated invasive potential in vitro and increased lung colonization in vivo at day 12 after 
transgene induction. By global gene expression analysis in partially reprogrammed cells, I 
identified SNAI3 as a novel invasion-related marker in human melanoma. Protein expression 
of SNAI3 correlates with tumor thickness in primary melanomas and thus, might be of 
prognostic value for patient stratification. 
Partial reprogramming of murine melanoma cells is an innovative in vitro model to study 
phenotype switch-associated gene expression and identified SNAI3 as a novel invasion-
related marker with potential for clinical application. 
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Zusammenfassung 
Die größte Herausforderung bei der Therapie des Malignen Melanoms ist die hohe Plastizität 
der Melanomzellen. Diese führt dazu, dass Melanomzellen schnell Resistenzen gegen 
Therapieansätze bilden, was letztendlich zu Therapieversagen und der hohen Todesrate 
beim Malignen Melanom führt. Ein immer wichtiger werdendes Konzept, das die 
Umwandlung von stark proliferierenden und wenig invasiven zu langsam proliferierenden, 
aber dafür hoch invasiven Melanomzellen beschreibt, ist der sogenannte Phänotyp-Wechsel. 
Trotz ihrer Notwendigkeit, um die molekularen Mechanismen zu untersuchen, die die 
zelluläre Plastizität induzieren, sind in vitro Modelle zur Untersuchung dieses Phänotyp-
Wechsels bisher kaum etabliert. In dieser Arbeit zeige ich, dass der Abbruch der 
Reprogrammierung muriner HCmel17 Melanomzellen diese in langsame wachsende Zellen 
mit stark erhöhter Invasionskapazität umwandelt. Ich zeige, dass Reprogrammierung muriner 
Melanomzellen ein stabiler und zeitabhängiger Prozess ist, der die globale Genexpression 
schrittweise verändert. Im Detail zeichnen sich Zellen an Tag 12 der Reprogrammierung 
durch erhöhtes Invasionspotential in vitro und erhöhte Lungeninfiltration in vivo aus. Des 
Weiteren habe ich anhand globaler Genexpressions-Analyse der partiell reprogrammierten 
Zellen den Transkriptionsfaktor SNAI3 als neuen invasionsassoziierten Marker für humane 
Melanome identifiziert. Proteinexpression von SNAI3 korreliert mit der Tumordicke in 
primären Melanomen und besitzt dadurch Potential für die klinische Anwendung, 
beispielsweise als prognostischer Marker für die Einteilung in Patientenkohorten. 
Zusammenfassend ist die partielle Reprogrammierung muriner Melanomzellen ein 
innovatives in vitro Modell, um die Genexpression zu untersuchen, die mit dem Phänotyp-
Wechsel in Melanomzellen einhergeht. Dieses System habe ich genutzt um den neuen, 
invasionsassoziierten Marker SNAI3 zu identifizieren. 
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1. Introduction 
This thesis covers two main areas of research: melanoma, as the cancer of interest, and 
reprogramming, as a technical tool used to gain novel insights into melanomagenesis. The 
first part of the introduction gives an overview of melanoma and its current therapeutic 
challenges. This section focuses on molecular resistance mechanisms against targeted 
therapy and the role of melanoma cells’ tremendous plasticity for therapy resistance. In the 
second part stem cells, pluripotency, reprogramming and its connection to cancer will be 
discussed. The third part introduces SNAI3, which I identified, using partial reprogramming, 
as a promising invasion-associated marker with prognostic value for melanoma patients. 
1.1. Melanoma 
Malignant melanoma is a tumor with high morbidity rates and increasing incidence. Since the 
1930’s, the risk for an American to develop melanoma in the United States has risen more 
than 18-fold, as stated in 1996 [1]. With 20 diagnoses per 100,000 in 2012, Germany is the 
17th country on the list of incidence [2]. Incidence and mortality hot spots are located in 
Australia and New Zealand, where there is high ozone depletion [2]. This can in part be 
explained by the close connection between ultraviolet (UV)-radiation and melanomagenesis 
[3]. 
With around 232,000 new cases diagnosed in 2012 malignant melanoma is the 19th most 
common cancer worldwide [2]. Although malignant melanoma only accounts for less than 
two percent of all skin cancers it is responsible for the vast majority of skin cancer related 
deaths highlighting the aggressiveness of this cancer type and the need for improvement of 
therapies [4]. 
1.1.1. Melanoma Origin 
Melanomas arise upon malignant transformation of melanocytes, the pigment-producing cells 
within the skin that generally protect skin cells from UV-radiation induced DNA-damage. 
Melanocytes represent the second largest cell population within the skin after keratinocytes 
and are located and consistently distributed in the basal layer of epidermis [5]. In order to 
fulfill their protective role, upon UV-radiation melanocytes produce the pigment melanin in 
specialized organelles called melanosomes, which is transferred to adjacent keratinocytes 
[6]. Once relocated into the keratinocyte, the pigment accumulates around the nucleus 
building a photo-protective barrier against UV-radiation [7]. On a molecular level, 
melanocytes are characterized by the expression of a set of genes linked to melanin 
 - Introduction -  
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production including tyrosinase (Tyr), tyrosinase-related protein 1 and 2 (Tryp1, Tryp2/Dct), 
melanosomal matrix proteins (Pmel17, Mart-1) and microphthalmia transcription factor (Mitf), 
which is one of the most important key players in melanogenesis [8]. 
During embryonic development, melanocytes are generated from the neural crest population, 
which also gives rise to mesenchymal and neural derivatives including neurons, glia, and 
endocrine cells [9]. After the differentiation of the embryonic disc into the neuroectoderm 
during early embryogenesis, neurolation occurs. This process describes the folding of the 
neural plate into the neural tube that will give rise to future central nervous system elements 
including the brain and spinal cord. During this neurolation process, a group of cells derived 
from the edges of the neural plate undergoes a phenotypic change from the epithelial to the 
mesenchymal type, which are called neural crest cells (NCCs). Directly after formation of 
these multipotent cells, they acquire migratory properties, separate from the neuroepithelium 
and progressively become lineage-restricted [8,10,11]. Dependent on their anatomical 
localization, NCCs form different functional groups, one of which is the trunk neural crest that 
further undergoes one of two major pathways [12]. One population migrates ventrolaterally 
forming the dorsal root ganglia that contain, among others, sympathetic ganglia and sensory 
neurons. In contrast, those neural crest cells that migrate dorsolaterally into the ectoderm 
towards the ventral midline become melanocytes. 
The precursor cells of melanocytes – melanoblasts – arise on the neural crest cells’ journey 
through the dermis and already comprise melanocyte-associated features but do not produce 
melanin yet [13]. The most commonly listed molecular markers include the tyrosine kinase 
receptor KIT (c-KIT); melanocyte-associated transcription factors such as Mitf, Sox10, Pax3 
and the melanogenic enzyme Tyrp2 but in contrast to fully differentiated melanocytes, the 
precursors lack Tyr expression [14–16]. Tyr is only expressed when melanoablasts reach 
their final destination within the basal lamina and become terminally differentiated 
melanocytes [14]. 
In addition to this classical understanding of melanocyte development recent studies 
revealed that there is another origin for this cell type (reviewed in [14]). Studies in mice using 
lineage-tracing experiments suggest a major contribution of melanocytes from Schwann cell 
progenitors in the postnatal skin. In this scenario, NCCs, which fail to acquire a neuronal fate, 
associate with nerves and gain a Schwann cell precursor fate. Dorsal and ventral branches 
of the spinal nerve guide these precursors to cutaneous locations. When reaching the ends 
of nerves, some Schwann cell precursors acquire a melanocyte-fate and migrate to the skin 
where they vastly proliferate and populate the skin [14]. 
 - Introduction -  
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1.1.2. Important mutations in melanoma 
Cellular differentiation is induced by activation of particular signaling cascades in order to 
translate extracellular signals to gene expression and ultimately induce cellular development. 
In melanocytes, the mitogen-activated protein kinase (MAPK) pathway is one of the essential 
signaling cascades that drives melanogenesis but is also involved in malignant 
transformation of melanocytes. MAPK signaling involves a set of particular players and a 
phosphorylation cascade (schematically displayed in Figure 1). In melanoma cells, the 
MAPK pathway includes rat sarcoma (RAS) protein, rapidly accelerated fibrosarcoma (RAF) 
protein and further downstream the mitogen-activated protein kinase kinase (MEK) and the 
extracellular signal-regulated kinase (ERK)1/2 [17]. Activated RAS-RAF-MEK-ERK signaling 
conducts growth and survival signals upon ligand binding and a subsequent phosphorylation 
chain. Activating ligands include a variety of growth factors, i.e. epidermal growth factor 
(EGF), platelet-derived growth factor (PDGF), and nerve growth factor (NGF) as well as 
ligands for G-protein-coupled receptors (GPCRs) and cytokines [18]. Ligand binding to 
tyrosine-receptor-kinases results in exchange of guanosine diphosphate (GDP) to guanosine 
triphosphate (GTP) in the G-protein RAS that initiates phosphorylation of membrane-
recruited RAF [19]. Phosphorylation-activated RAF can induce downstream signaling by 
triggering phosphorylation of MEK that in turn phosphorylates ERK. ERK phosphorylation 
leads to stimulated gene expression of survival-, differentiation- and cell cycle progression- 
associated genes [17]. 
MAPK signaling and especially RAF molecules have gained more importance and clinical 
value after studies have demonstrated the high occurrence of activating RAF mutations in 
several different human cancers [20]. RAF-hyperactivation eventually results in uncontrolled 
MAPK signaling, driving cellular proliferation and survival and thus malignant transformation. 
Melanoma heavily relies on RAS/RAF/MEK/ERK signaling [20]. A mutation study showed 
that in general 48 % of metastatic melanoma patients harbor some kind of an activating 
BRAF (v-raf murine sarcoma viral oncogene homolog B) mutation, one of the family 
members of RAF proteins [21]. Interestingly, of all melanoma patients with BRAF-mutations, 
about 74 % demonstrate a substitution of valine by glutamic acid at codon 600 (V600E), 
which makes this mutation as the most common in melanoma. In addition, the replacement 
of the exact same valine by lysine (V600K) is observed in 20 % of melanoma patients while 
6 % show other genotypes [21]. Next to RAF mutations, the upstream regulator RAS is also 
affected in melanoma with approximately 18 % of melanoma patients exhibiting a NRAS 
mutation [22]. Together, this supports the hypothesis that the RAS/RAF axis constitutes a 
major signaling checkpoint in the MAPK pathway that will promote malignant transformation 
upon uncontrolled hyperactivation [17]. 
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Figure 1  Common mutations, targeted therapy and resistance mechanisms in melanoma 
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In addition to mutations occurring directly within the MAPK signaling pathways, other genes 
are mutated in melanomas including PTEN (phosphatase and tensin homologue) and 
CDKN2A (Cyclin-dependent Kinase Inhibitor 2A). Loss or inactivating mutations in PTEN are 
present in melanoma cells lines and melanoma patients [23] (Figure 1). The loss of PTEN 
results in hyperactivation of Protein-Kinase-B(PKB)/AKT-signaling whereby induction of 
apoptosis is downregulated. The CDKN2A gene encodes for several different transcripts 
including those for two major tumor suppressor proteins, P16INK4a and P14ARF, which both act 
as cyclin dependent kinase (CDK) inhibitors, although different in their structure and 
mechanism of action [24]. P14ARF stabilizes the tumor suppressor protein P53 by inhibiting 
the E3 ubiquitin-protein ligase MDM2, a protein that triggers degradation of P53 and with 
intact cellular P53 cell cycle arrest is induced via P21-mediated CDK inhibition [24]. In 
contrast, P16INK4a regulates cell cycle control by targeting the retinoblastoma (RB) pathway. It 
inhibits CDK4/6-cyclineD1 complexes and thus prevents the phosphorylation of RB proteins 
leading to stable RB-E2F complexes. In the presents of these complexes elongation is 
inhibited and cells do not enter the S-phase of the cell cycle, thus they are primed for 
senescence and differentiation [25]. Dysfunction of these two important cell cycle control 
regulators due to loss of the CDKN2A locus can lead to malignant transformation. 
Hemizygous or homozygous loss of the CDKN2A gene occurs in about 56 % of melanoma 
patients [26]. 
1.1.3. Targeted therapy – BRAF inhibition 
Vemurafinib was the first targeted therapy compound approved by the U.S. Food and Drug 
Administration (FDA) in 2011 for BRAF-mutated malignant melanoma patients. It reversibly 
competes with adenosine-triphosphate (ATP) to bind to the kinase domain of BRAF 
ultimately inhibiting BRAF-induced MEK-activation [27]. Results from a randomized study 
comparing the common chemotherapeutic agent dacarbazine with vemurafinib in previously 
untreated melanoma harboring V600E-mutations demonstrated improvement in progression-
free survival (6.9 versus 1.6 months) and in median overall survival (13.2 versus 9.6 months) 
[28]. In contrast to its improvement in progression-free survival as the most important 
parameter for the patient, vermurafinib can lead to adverse events including development of 
cutaneous squamous cell carcinoma, kerato-acanthoma, and skin papilloma [28]. 
Upon successful introduction of the first targeted therapy compound, researchers and 
clinicians introduced another BRAF inhibitor to the market. In 2013, the FDA and the 
European Union approved dabrafenib on the basis of a randomized trial of patients with 
previously untreated BRAFV600-mutated melanomas comparing the BRAF inhibitor with the 
standard chemotherapy, dacarbazine [29]. Similar to vemurafinib, dabrafenib increased 
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median progression-free survival from 2.7 months for dacarbazine treated patients to 5.1 
months.  
Despite the success of targeted therapy, melanoma patients acquire resistance to these 
RAF-inhibitors approximately six months after initial administration. The underlying 
mechanisms of resistance drive disease progression and understanding these mechanisms 
is required for successful melanoma therapy. Interestingly, no secondary mutations in the 
drug target BRAF upon treatment have been identified neither in samples from patients nor 
in cell lines [30]. Melanoma cells rather re-activate the RAS-RAF-MEK-ERK cascade through 
different molecules up- and downstream of BRAF. Signal transducers upstream of BRAF 
include RAS, which recruits RAF to the membranous receptor tyrosine kinase complex to be 
activated. Cells with mutated NRAS (ca. 15 % of melanomas) or hyperactivated wildtype 
RAS show enhanced MEK/ERK signaling upon BRAF inhibitor treatment leading to therapy 
failure (reviewed in [31]). In addition to this upstream modulation, it is known that BRAF 
activity can be substituted by activation of CRAF and ARAF, paralogs of BRAF. These RAF 
molecules are activated in vemurafenib-resistant cell lines and knockdown of CRAF re-
sensitizes vemurafenib-resistant clones to BRAF inhibition [32]. In addition to BRAF 
paralogs, other kinases are involved in MEK/ERK activation. The non-RAF MAP3-Kinase 
COT1 was identified in a complementary DNA screen for kinases that prevent BRAF inhibitor 
(PLX4720)-mediated cell growth arrest [33]. This study demonstrated that BRAF inhibition in 
cell lines leads to increased COT1 expression. In addition, biopsy studies revealed that 
COT1 upregulation is an adaptive response to vemurafenib (PLX4032) treatment ultimately 
causing resistance. These results are of clinical interest since two out of three tumors from 
melanoma patients, who are resistant to BRAF inhibition, show elevated COT1 mRNA [33]. 
Also, therapy resistance is in part caused by paradoxical activation of RAF via RAF 
dimerization in BRAF wildtype cells [34]. The pan-RAF inhibitor TAK-632 inhibits the kinase 
activity of these RAF dimers resulting in reduced wildtype-RAF signaling and thus indicates a 
more effective treatment without resistance caused by vemurafenib- or dabrafenib-induced 
paradox wildtype RAF activation [35]. 
Besides these mechanisms, cells can possess endogenous or acquired resistance to BRAF 
inhibition due to the modulation of signal transducers downstream of RAF. In this context, 
mutated MEK is one of the clinically relevant mechanisms [36]. Alterations in ERK1/2- 
regulated cell cycle events can also contribute to insensitivity against BRAF inhibition. 
Cyclin D1 in part mediates cell cycle control in a manner that increased cyclin D1 leads to 
hyper-phosphorylation of RB and ultimately to cell cycle progression from G1 to S-Phase. 
This check point is part of a melanoma resistance mechanism and approximately 25 % of 
mutant BRAF melanoma cell lines and tumor samples harbor genomic amplifications in 
Cyclin D1 [37]. 
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1.1.4. Targeted therapy – MEK inhibition 
Targeting the MEK/ERK signaling downstream of BRAF is proven successful with trametinib, 
a small-molecule inhibitor of MEK1/2. The FDA approved its use in May 2013 for treatment of 
BRAF V600E- or V600K- mutated melanomas [38]. Its efficacy was tested in randomized 
phase III trial involving patients with the required mutations, in which trametinib was 
compared to standard chemotherapy with dacarbazine similar to the first trials for 
vemurafenib [39]. Overall survival at six months was increased from 67 % to 81 % comparing 
trametinib with dacarbazine. Although patients suffered from adverse side effects including 
heart toxicity, other side effects like cutaneous neoplasms as reported for vemurafenib 
treatment were absent [39]. 
1.1.5. Targeted therapy – combined BRAF and MEK inhibition 
The observation that trametinib-treated patients do not suffer from cutaneous neoplasms and 
the resistance development under monotherapy with vemurafenib or dabrafenib led to the 
design of a combinational trial with dabrafenib and trametinib. Due to promising results of the 
combinational therapy in a phase I and II study in 2012 the FDA approved the combination 
regimen in January 2014 [40]. In a phase III trial the combination of dabrafenib and 
trametinib was compared with dabrafenib monotherapy and revealed improved progression-
free survival from 5.8 months (monotherapy) to 9.4 months (combination) [41]. The median 
duration of therapy response was prolonged from 5.6 to 10.5 months with stronger tumor 
regression in the combinational setting (76 % versus 54 % with complete or partial response) 
[41]. In addition, a recent study confirmed the advantage of combined inhibition of mutated 
BRAF and MEK using vemurafenib in combination with the MEK inhibitor cobimetinib. 
Progression-free survival was prolonged from 6.2 months to 9.9 months [42]. 
In conclusion, the combinational therapy regimen reveals two main advantages, i.e. (i) the 
delay of acquired monotherapy resistance, and (ii) the reduced incidence of squamous cell 
carcinoma [41]. However, despite these great advantages, this treatment results in increased 
adverse events and total required hospitalization raises from 2 % to 25 % [41]. 
Although targeted therapy improves anti-melanoma therapy, the high plasticity of melanoma 
cells allows a variety of resistance mechanisms that impede therapy success (Figure 1). 
Next to the mechanisms described above, melanoma cells also activate signaling pathways 
independent from MEK/ERK signaling that ultimately results in accelerated cell cycle 
progression and therapy resistance despite inhibited MEK/ERK signaling. It was shown that 
cancer cells can bypass MEK/ERK inhibition by activating PDGF-signaling [30] or by 
activation of the AKT/PIP3 pathway [43]. For example, one study showed that MEK inhibition 
in combination with a phosphatidylinositol-3 kinase inhibitor induced cell death in RAF-
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inhibitor resistant cell populations [43]. These data reveal novel options for targeting 
melanoma progression and therapy resistance besides RAF and MEK inhibition. 
1.1.6. Targeted therapy – tyrosine kinase inhibitors 
Imatinib is a small molecule inhibitor mainly used in patients with chronic myeloid leukemia. It 
competes with adenosine triphosphate and thus, inhibits several tyrosine kinases, including 
bcr-abl, c-KIT, and PDGF-R. Due to c-KIT amplifications or activating mutations in melanoma 
patients [44], clinical trials were designed to test the effect of this drug in anti-melanoma 
treatment. C-KIT is a transmembrane tyrosine kinase mediating cell cycle progression via 
activation of MAPK- and PI3K-cascades and thus, its activation leads to tumor progression if 
not properly controlled. The phase II trial of imatinib in melanoma patients harboring c-KIT 
mutations or amplifications revealed durable responses in 16 % of patients with a median 
time to progression of 12 weeks [45]. In contrast to the resistance mechanisms seen in 
BRAF-inhibitor treated patients, c-KIT-inhibited cells circumvent treatment by the acquisition 
of secondary c-KIT mutations (Figure 1, [46]). 
In summary, targeted therapy provides a great advantage over conventional chemotherapy 
for anti-melanoma treatment. However, extensive prolongation of progression-free and 
overall survival is hampered by melanoma cells’ resistance mechanisms. Also, patients 
suffering from malignant melanoma without carrying particular mutations described above 
are in need of different therapy options. In fact, some therapy alternatives are available 
including immunotherapy and oncolytic viruses. Immunotherapy involves antibody-directed 
inhibition of immunosuppression that is mediated by impeding the crosstalk between T cells 
and their environment [47–50]. In addition, the first-ever phase III clinical trial for an oncolytic 
virus was conducted for melanoma patients with promising results after interim analysis [51]. 
Conversely, after closing the trial in 2013, preliminary analysis revealed that despite 
significant elevation of dose response rates, the overall survival of patients receiving the 
oncolytic treatment was not significantly improved compared to patients with control 
treatment [52]. Next to targeted and immune-effecting therapies, also novel 
chemotherapeutic compounds are under investigation. Nab-paclitaxel is a novel 
chemotherapeutic agent, which is delivered as an albumin-bound compound [53]. This 
facilitates binding to the tumor due to albumin’s water-soluble properties, ultimately resulting 
in inhibition of mitosis and increased tumor cell apoptosis with an advantageous 
pharmacokinetic profile [53]. A phase III clinical trial revealed an increase in both 
progression-free survival and interim overall survival when melanoma patients were treated 
with nab-paclitaxel compared to dacarbazine regardless of the BRAF-mutation status [54].  
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1.1.7. Therapeutic challenges 
The high risk for metastasis is a major issue once melanoma has been diagnosed. Thus 
early diagnosis is crucial for the chance to cure melanoma patients. Great success has been 
made by finding novel targets for anti-melanoma therapy that result in good clinical 
responses (see sections 1.1.3-1.1.6 targeted therapy) but rapidly emerging resistance to 
every therapeutic intervention results in the barely improved treatment of this cancer once it 
has metastasized. The high plasticity of melanoma cells leads to evasion of therapy and 
thus, is the major challenge for anti-melanoma therapy. Despite responsive treatment at the 
beginning of therapy, cells alter their tolerance to drugs, which ultimately leads to 
reoccurrence of tumors and metastatic burden causing the high mortality rate in melanoma 
[1,2]. Therefore, understanding the dynamic phenotypes of melanoma cells will help 
identifying different strategies of anti-melanoma therapy, which are independent of the 
tumor’s mutational status. This approach will open novel therapeutic options especially for 
patients without common mutations. 
1.1.8. Cancer stem cells in melanoma 
In order to identify the mechanisms behind the high plasticity, different attempts have been 
made including the investigation of cancer stem cells in melanoma. Cancer has been thought 
of as a homogenous tumor mass before research revealed the opposite: Tumors generally 
consist of different cells that show different morphology, gene expression and functional 
properties. Huge effort is being made to analyze tumor subpopulations and the concept of 
cancer stem cells (CSCs) since John E. Dicks provided first evidence for their existence in 
1994 [55]. CSCs are described to (i) exist as a small subpopulation within the tumor bulk, (ii) 
be rather slowly proliferative making them immune against proliferation-dependent 
chemotherapeutics, and (iii) having the power to repopulate the whole tumor with its original 
heterogeneity. The CSC-theory describes a tumor to be hierarchically organized and to 
consist of different subpopulations with different capabilities regarding clonogenic and 
tumorigenic potential. CSCs initiate and support tumor progression, metastasis and 
chemoresistance [56]. These attributes make CSCs the perfect target for anti-cancer therapy 
leading to complete cure without relapse. 
In acute myeloid leukemia, this CSC model has been conclusively established and specific 
CSCs or tumor initiating cells (TICs) are well described [55,57,58]. In addition, CSC were 
found in pancreatic cancer [59], in head and neck squamous cell carcinoma (reviewed in 
[60]), in mesenchymal neoplasms [61] and in colorectal cancer [62]. Despite the research 
progress in other cancer types regarding the identification and isolation of CSCs, different 
studies about the presence of CSCs in melanoma have shown conflicting results. Expression 
of a variety of molecules has been described as melanoma stem cell markers but succeeding 
 - Introduction -  
- 17 - 
 
research has often contradicted published data. Initially, enhanced tumorigenic potential in 
melanoma cells expressing the ATP-binding cassette (ABC) transporter ABCG2 and the 
surface marker cluster of differentiation (CD) 133 were reported [63] and these markers have 
already been associated with CSCs in other solid malignancies including brain tumors [64]. 
In addition, another study demonstrated that ABCB5-positive melanoma cells are capable of 
tumorigenesis, self-renewal and differentiation into a heterogeneous population when 
primary patient-derived tumor cells are serially transplanted into NOD/SCID mice. In contrast, 
their ABCB5-negative counterparts lack these tumor initiating properties indicating ABCB5 as 
a marker for melanoma stem cells [65]. 
The surface marker CD271 (p75/ Nerve Growth Factor-Receptor/ NGFR) is argued to be a 
genuine stem cell marker [66]. CD271-positive cells from fetal nerves of rats represent a 
subpopulation that is enriched in cells that are phenotypically and functionally comparable to 
neural crest stem cells, indicating that CD271 is a potential marker of stemness in 
neuroectoderm-derived cells [67]. Distribution of CD271 within human malignant tissue 
resembles that of normal tissue suggesting that also in tumors a subpopulation of CD271-
positive cells is present [68]. Today, the potential of CD271 to label melanoma stem cells is 
discussed controversially. Although some groups cannot find indications of a stable CD271-
positive CSC-subpopulation in melanoma [69], recently published data provide evidence that 
CD271-positive cells have significantly increased tumorigenic potential [66,70]. The huge 
variation between results regarding CD271-positive melanoma stem cells can in part be 
explained by differences in methodologies. Next to the method for single cell extraction from 
primary melanomas and surface marker stability, also the immune competence level of mice 
used for injections can have great impact on tumorigenic potential of melanoma cells [56,66]. 
Another report stated that human melanoma cells with high aldehyde dehydrogenase 
(ALDH) activity are enriched in tumorigenic cells over unfractionated cells in NOD/SCID as 
well as in NSG mice. Next to enhanced tumorigenicity of ALDH-positive cells, they also 
possess superior self-renewal ability making ALDH a potential melanoma stem cell marker 
[71]. In addition, receptor activator of nuclear factor κ B (RANK) expression is co-expressed 
with ABCB5 and CD133 connecting this receptor to melanoma stem cells [72]. Its expression 
is significantly increased in peripherally circulating melanoma cells and metastases from 
stage IV melanoma patients compared with tumor cells from stage I melanoma patients. The 
authors suggest that RANK is involved in the development and maintenance of melanoma-
initiating cells and possibly in metastatic spreading [72]. 
Despite all evidences showing that these markers label melanoma stem cells as a stable 
subpopulation within melanomas other studies revise this concept and show that melanoma 
cells feature a highly dynamic expression of genes. Investigations on the lysine demethylase 
5b (KDM5b/Jarid1b) reveal a more dynamic and transient presence of CSCs, thus 
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contradicting the classical CSC model [73]. The study suggests a dynamic expression of 
KDM5b that is required for long-term melanoma maintenance [73]. In the end, the classical 
CSC model becomes questioned not only due to dynamic expression of all potential 
melanoma stem cells markers but also because of studies showing that melanoma initiating 
cells are not rare at all and one in four to one in nine melanoma cells can establish 
melanoma growth in mice models [69,74]. 
In summary, genes associated with melanoma stem cells are dynamically regulated and fail 
to distinguish between tumorigenic and non-tumorigenic cells. Recent studies display that not 
specific individual genes are responsible for the particularly aggressive growth in melanoma 
but that these cancer cells rather hijack portions of the embryonic neural crest invasion 
program [75]. This observation links melanomagenesis tighter to its developmental path by 
focusing on the migratory capabilities of NCCs that might in part explain the extreme 
metastatic power of melanomas compared to cancers derived from other lineages. 
1.1.9. De-differentiation, EMT and invasion in melanoma 
The origin of melanocytes from NCCs is of great importance for melanoma research since 
the neural crest population has unique features connecting it to aggressive cancer. The 
natural gene expression profile of NCCs correlates with that of transformed melanocytes 
[76]. Since the conversion from an epithelial to mesenchymal cell type is essential during 
normal embryogenesis and particularly attained by the neural crest, melanocytes are 
epithelial cells that have already been subjected to epithelial-to-mesenchymal-transition 
(EMT) during their normal development. Thus, melanocytes are thought to possess an 
inherent predisposition to gain EMT-induced invasive potential but the true impact of genes 
associated with the neural crest remains to be fully evaluated [75–77]. Some studies suggest 
that de-differentiation of melanoma cells towards a neural crest-like type is a major step in 
order to gain invasive potential and enhance disease progression [78]. Following this 
assumption it is of interest whether forced differentiation can revert invasiveness in these 
cells. One study provided experimental evidence for this kind of anti-melanoma tactic. The 
prodrug 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin (TMECG) is a dihydrofolate reductase 
inhibitor and requires activation by melanocyte-specific tyrosinase. Thus, tyrosinase 
expressing melanoma cells can be pushed into apoptosis by TMECG-induced depletion of 
the thymidine pool and ultimately inhibition of DNA synthesis [79]. Since de-differentiated 
melanoma cells lose expression of melanocyte-specific genes, i.e. Mitf and Tyr, re-activation 
of these genes is required for this approach. Interestingly, the differentiation-agent 
methotrexate (MTX) induces expression of tyrosinase in de-differentiated melanoma cells by 
elevated Mitf expression and thus, MTX/TMECG combination therapy results in apoptosis 
under experimental conditions in vitro and in vivo [79]. 
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In contrast, other experiments propose that invasive expression patterns are independent 
from neural crest signaling and that expression of neural crest-related genes labels 
melanoma cell populations with low invasive potential [80]. Despite the controversial data 
regarding neural crest-related mechanisms that are taken over by melanoma cells, initiating 
metastasis is a crucial step in disease progression and understanding its molecular 
mechanisms will help improve therapy. Obviously, motility is a defined requirement for any 
cancer cells to become invasive and induce metastasis. Since melanoma is a malignancy 
derived from non-motile cells, migration and ultimately invasion and metastatic potential need 
to be acquired throughout disease progression. This section discusses some key signaling 
pathways involved in common and melanoma-specific invasion programs.  
 
Generally, there are two main modes that are used by cancer cells to acquire motility and 
that ultimately lead to tumor dissemination and metastatic spread. The most common way is 
through increased proteolytic activity via the upregulation of matrix-degrading enzymes 
including matrix-metalloproteases (MMPs). MMPs are well-established markers for invasive 
properties and allow poor prognosis for a variety of cancer types including colorectal cancer 
[81], breast cancer [82], head and neck squamous cell carcinoma [83] and lung cancer [84]. 
In melanoma, expression of several MMPs correlates with tumor progression and invasive 
capacity in vitro and in vivo. Membrane type-I matrix metalloproteinase (MT-MMP1, MMP14), 
for example, is generally involved in melanoma growth and progression since its expression 
correlates with invasive potential through matrigel in vitro and facilitates growth upon intra-
dermal injections of melanoma cells lines in vivo [85]. Also, upon de-differentiation of 
melanoma cells MMP14 expression was elevated and invasive potential increased [86]. In 
addition, in vitro experiments revealed that MMP2 activity modifies adhesion features as well 
as the interaction with, and extension on components of the extracellular matrix (ECM) [87]. 
Since loss of adhesion and the capability of anchor independent growth are essential 
elements of invasive cancer cells, MMP2 became an interesting regulator of cancer 
spreading [87]. In vivo analysis of melanoma cells expressing latent or functionally active 
MMP2 demonstrated that increased endogenous MMP2 correlates with elevated invasive 
potential [88]. Next to MMP14 and MMP2, also MMP3 and MMP9 are expressed at invasive 
tumor borders in vivo or enhance invasive properties in melanoma cell lines upon exogenous 
overexpression in vitro [89,90]. 
 
The second central pathway to gain cellular motility involves upregulated RHO-signaling 
through RHO-Kinase (ROCK). This mechanism is independent of ECM-proteolysis since 
cellular motility is acquired through adjustment to 3D-environment by contraction of the 
cortical actin network. This is accompanied by transient membrane blebbing and subsequent 
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retraction of cells. Thus, cells can invade through 3D-structures by changing their 
morphology to a small, round shape and enable movement by membrane re-organization 
representing a amoeboid-like movement pattern [91]. RHO enzymes comprise one subgroup 
of RAS-related small guanosin-triphosphatases (GTPases) and they are dominantly involved 
in cytoskeleton remodeling since they control actin polymerization and bundling of actin 
filaments [92]. This modification of the cytoskeletal arrangement is crucial to induce 
amoeboid-like motility and introduces RHO signaling as a major pathway in control of cellular 
motility. Importance of RHO signaling in melanoma progression is demonstrated by its 
requirement to maintain metastatic potential in human melanoma cells [93]. This study 
demonstrated that overexpression of RHO-C is required for metastatic potential of human 
melanoma cells in xenograft transplantation assays. Strikingly, overexpression of this single 
gene is sufficient to enhance experimental metastasis formation in vivo and thus, 
cytoskeleton remodeling induced by RHO-C signaling might be a key element in metastasis 
formation [93]. 
In cancer cells these different modes of motility and metastatic invasion are reversible. This 
might in part explain the discouraging results from clinical trials using MMP inhibitors as 
metastasis blockers (reviewed in [94]) since tumor cells escape MMP-dependency by 
switching to other migratory strategies. In experimental settings it is proven that tumor cells 
can shift their migratory behavior from the proteolytic manner towards the proteolysis-
independent, amoeboid-like form without any impairment of their invasive capacity [95].  
1.1.10. Cellular phenotype switch during melanoma progression 
Melanoma cells seem to de-differentiate in order to enhance their migratory and invasive 
capacity. Therefore, not all factors that are essential for the initial malignant transformation of 
melanocytes are also crucial for the acquisition of invasive properties. Regarding their gene 
expression, melanoma cells can be separated in vitro into cohorts that show distinct 
proliferative and invasive behavior [80]. One set of cells shows high proliferation and low 
motility whereas the other group comprises strong invasion potential but little proliferation 
[80]. Of note, these phenotypes correlate with metastatic potential but are independent from 
any BRAF mutations indicating a tumor progression program that is detached from genetic 
aberrations involved in melanoma initiation [80]. In addition, the phenotype switch of 
melanoma cells occurs in a dynamic manner so that melanoma cells, independent of their 
original proliferative or invasive phenotype, induce growth of tumors that comprise of cells 
exhibiting both phenotypes [96]. 
It is further shown that highly proliferative melanoma cells that are subjected to a hypoxic 
environment convert into highly invasive cells whereas originally invasive cells do not 
respond to hypoxic stimuli. Researchers suggest that proliferative melanoma cells are 
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subjected to hypoxic microenvironments in vivo and that this condition is sufficient to induce 
de-differentiation and results in increased invasion [97].  
After the emergence of the melanoma phenotype switch as a concept of melanoma plasticity, 
an increasing number of markers have been identified that correlate with and induce the 
switch from a proliferative to an invasive phenotype. The inversely expressed receptors 
ROR1 and ROR2, which negatively regulate each other, serve as potential indicators for this 
conversion. After hypoxic conditions were applied in vitro the expression of ROR1 in highly 
proliferative melanoma cells shifted towards a ROR2-dominated pattern and correlated with 
elevated invasion [98]. This indicates that microenvironmental stimuli, such as hypoxia, are 
sensed by these receptors to induce an invasive signaling cascade. This progression from a 
proliferative to an invasive cell type is also connected to therapy resistance. Invasive 
expression patterns including hypoxia-induced ROR2 upregulation were shown to correlate 
with clinical responses to BRAF inhibition [98]. Another study showed that melanoma cells 
grown as spheroids in a neural cell crest display the phenotype switch with concomitant 
increase in stem cell marker expression including Nanog and Oct4 [78] (discussed in section 
1.1.9). Interestingly, the occurrence of this invasive phenotype was connected to PHF19 
expression [78]. PHF19 is a protein that is involved in polycomb group repressive complex 
(PRC) 2-mediated inhibition of stem cell-associated genes during embryonic differentiation 
[99]. Thus, melanoma cells undergoing phenotype switching suppress stem cell marker-
inhibition through decreased PHF19 expression and subsequent de-differentiation is 
associated with increased invasiveness [100]. 
BRN2 is another gene that is expressed in a subpopulation of melanoma cells that are 
negative for MITF [101]. Functionally, BRN2 directly represses MITF expression and 
correlates with enhanced invasion capacity of melanoma cells [101]. Further investigations 
revealed that these BRN2 expressing cells within the primary tumor are the cells with 
extravasation capacity indicating enhanced invasion in vivo [102]. Thus, non-pigmented cells 
highly expressing BRN2 are found in the circulation indicating that they possess 
extravasation capability. However, after entering second sites cells re-adjust their expression 
and switch to increased MITF expression so that metastatic tumors mainly comprise of 
pigmented, MITF-positive and BRN2-negative cells [102]. Therefore, hypoxic conditions 
within primary tumors can convert proliferative cells into highly motile ones that enter the 
circulation. After homing to distant organs, cells increase their proliferative capacity in order 
to establish a novel metastasis. 
 
In summary, melanoma cells possess the ability to alter their proliferation and invasion 
capacity in response to environmental signals. This reversible phenotype switch enables 
melanoma cells to disseminate from the primary tumor and establish metastasis at 
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secondary sites, which exhibit the heterogeneity of the primary tumor. Interestingly, the 
differentiation status of melanoma cells has a huge impact on this phenotype switch: 
Expression of melanocyte-specific genes labels highly proliferative cells whereas increased 
invasion is accompanied by de-differentiation. Deeper understanding of the molecular 
mechanisms inducing the phenotype switch is required to fully discover the metastatic drive 
of melanoma cells and identify new targets for anti-melanoma therapy. 
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1.2. Stem cells and reprogramming 
This study uses reprogramming as a technical tool, so in the next section stem cells and 
cellular reprogramming will be discussed in order to give an outline of known techniques and 
important regulators. In addition, similarities between reprogramming and malignant 
transformation of cells will be summarized. 
1.2.1. Stem cells 
By definition, stem cells are cells, which possess unlimited self-renewal capacity in 
combination with the ability to generate progenies of a more differentiated state. The potency 
of specific stem cells depends on their range of differentiation potential and thus, stem cells 
can be divided into different stages: totipotent, pluripotent and monopotent stem cells. 
Mammalian totipotent stem cells are the only stem cells giving rise to all cells of the organism 
including extra-embryonic tissue required for implantation of the embryo and its proper 
development. This totipotency has only been determined for the zygote state of a 
mammalian embryo. After cleavage divisions of the zygote the so-called morula is generated. 
This cell cluster further separates into a blastocyst that consists of the extra-embryonic 
trophoectoderm and the inner cell mass (ICM) [103]. Shortly after the formation of this mixed 
ICM, cells segregate into the extra-embryonic primodal endoderm expressing Gata6 and the 
Nanog-expressing epiblast containing pluripotent cells that give rise to all embryonic tissues 
from every germ layer including germ cells (discussed in [104]). Cells within the epiblast of an 
embryo gradually lose their differentiation capacity and give rise to different types of 
multipotent cells, that form cells from different tissues within one germ layer, i.e. 
hematopoietic stem cells [105]. Monopotent stem cells are cells that fulfill the criteria of 
stemness but they only give rise to a single type of differentiated cells, such as epidermal 
stem cells generating keratinocytes throughout the life of humans [106]. 
For research and for clinical applications, especially pluripotent cells are of great interest 
since they contain the capability to generate any cell in the human body and thus, their 
potential for regenerative medicine is vast. Studying embryonic development in mice helps to 
understand the sources of this pluripotent cells, i.e. the inner cell mass of the blastocyst or 
the epiblast, respectively. These cells can successfully be cultured in vitro and by now, a 
large variety of murine embryonic stem cells (ESCs) are available [107,108]. Due to 
developmental processes described above, ethical issues are the limiting factor for 
investigating human pluripotent stem cells. Working with any kind of human embryonic stem 
cell is prohibited by law in most European countries including Germany [109]. It has already 
been shown that somatic cells can be converted into pluripotent stem cells using 
transplantation of somatic nuclei into enucleated oocytes [110] or cellular fusion with an 
oocyte [111,112]. However, these techniques still require embryonic stem cells and due to 
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coherent restriction in using human embryonic cells, stem cell research has been limited. 
The discovery of Yamanaka and colleagues opened up an entire new field of stem cell 
research with the induced pluripotent stem cells (iPSCs) they generated [113]. 
1.2.2. Reprogramming somatic cells into induced pluripotent stem cells 
In 2006, Yamanaka et al. demonstrated for the first time that somatic cells can be 
reprogrammed into a pluripotent state by forced expression of defined factors, the so-called 
Yamanaka-factors [113]. The authors use exogenous expression of Oct4, Klf4, Sox2 and c-
Myc (OKSM) by retroviral gene transfer in order to reprogram embryonic and adult murine 
fibroblasts into pluripotent stem cells [113]. This study initiated intense research on a variety 
of methodologies to induce pluripotency in somatic cells and to dissect the molecular steps of 
the reprogramming process. Following this new discovery in cellular plasticity, several assays 
became highly important in order to define the developmental potential of iPSCs. In this 
context, the least stringent functional assay is in vitro differentiation since no conclusion can 
be made regarding their in vivo potential. Therefore, a widely established in vivo assay to 
confirm the stem-like state of reprogrammed cells is the generation of teratomas upon 
subcutaneous injections into mice [114]. These tumors comprise of differentiated cells from 
all three germ layers and thus provide evidence for true pluripotency of iPSCs. In addition, 
chimera formation and germ line contribution after injection into the ICM of the blastocyst 
demonstrates pluripotency with higher stringency followed by the most exact test - the 
injection of cells into tetraploid-host blastocysts [115]. Since tetraploid cells cannot contribute 
to embryogenesis, embryos derived from these injections are so-called “all iPSC” embryos or 
animals. 
There are many possibilities to generate iPSCs. In addition to lenti- or retroviral gene 
transfer, there are several different non-integrating methods that are established to keep the 
cellular genome intact. Researchers successfully reprogrammed murine as well as human 
fibroblasts using continual transfection with plasmid vectors and subsequent transient 
expression of required transcription factors [116,117]. Also, adenoviral transfer [118,119] or 
sendai virus-mediated gene expression have been used as viral vectors of choice due to 
their non-integrating feature [120,121]. In addition to these DNA-based methodologies, other 
groups demonstrated successful reprogramming towards pluripotency by DNA-free 
technique such as messenger RNA transfection [122] or direct protein delivery [123]. Since 
reprogramming requires expression of certain genes and gene expression can be mediated 
by microRNA (miRNA)-controlled pathways, different miRNA clusters have been used to 
enhance iPSC generation or create iPSCs from human or murine origin without additional 
expression of exogenous transcription factors [124–126]. In 2013, researchers used a single, 
synthetic self-replicating RNA replicon derived from the Venezuelan equine encephalitis virus 
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to induce pluripotency in human fibroblasts [127]. This RNA expresses four reprogramming 
factors, Oct4, Klf4, Sox2 with c-Myc or Glis1 at consistently high levels with the advantage of 
directed degradation so that no exogenous RNA remains within the reprogrammed cell [127]. 
Another technique that possesses high potential to ultimately meet the needs for 
regenerative medicine is reprogramming somatic cells by administration of small molecule 
compounds. After the discovery that a specific combination of chemical compounds is 
sufficient to permit reprogramming from mouse fibroblasts in the presence of only Oct4 [128], 
all reprogramming factors could successfully be replaced by seven small molecule 
compounds that bind to nuclear receptors, histone-modifying enzymes and DNA-modifying 
enzymes as well as to protein kinases and signaling molecules [129]. This approach 
demonstrates that somatic cells harbor an endogenous pluripotency program that can be 
reactivated by the modulation of molecular pathways via small molecules in the absence of 
ectopic “master regulators” [129]. 
 
In summary, reprogramming is defined by accompanying processes that can be induced by 
several different methodologies including exogenous miRNA expression or transient 
treatment with small molecule compounds. However, the induction of a stable pluripotency-
associated gene expression network is essential for maintaining the high developmental 
potential of pluripotent cells.  
1.2.3. The circuit of pluripotency 
It is widely accepted that the most important players in pluripotency are Oct4, Sox2 and 
Nanog. These transcription factors are not only used to induce pluripotency [130] but their 
endogenous expression is key criterion in order to maintain pluripotency in cultured ESCs. 
Their unique expression pattern during early development suggests a major role of these 
transcription factors for the specification of embryonic stem cell identity [131–133]. The 
precise control of the master regulators’ expression is, for example, demonstrated by the 
restriction of Oct4 expression to ESCs, cells of the inner cell mass and to cells of the germ 
line [134]. Repression of Oct4 upon differentiation and lineage commitment and subsequent 
activation of Oct4-repressed developmental genes is crucial for normal development in 
mammalian organisms. Thus, massive expansion of poorly differentiated cells occurs upon 
systemic, ectopic Oct4-expression in adult mice underlining the importance of complete 
silencing of this pluripotency-associated factor during differentiation [135]. Regarding 
reprogramming, the importance of Nanog is demonstrated by proving that selecting for 
Nanog-expressing cells leads to superior reprogramming results [136] compared to initially 
established selection for Fbx15-positive cells [113]. Enhanced iPSC formation of Nanog-
positive cells is observed and established Nanog-iPSCs mimic DNA methylation patterns of 
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ESCs and can give rise to chimera formation indicating complete reprogramming into the 
ESC-state [136,137]. Nanog-selected iPSCs are also indistinguishable from ESCs regarding 
their global gene expression and their chromatin configuration in contrast to Fbx15-selected 
iPSCs [136]. In addition, reactivation of the inactivated X-chromosome in female cells is 
confirmed in Oct4- or Nanog-positive iPSCs [137]. These in vitro analyses of pluripotency are 
verified using the most stringent assays in order to define the stem-like state of these 
reprogrammed cells: Oct4- or Nanog-positive iPSCs generate postnatal chimeras upon 
blastocyst injection, contribute to the germ line [136–138] and generate “all iPSC-embryos” 
through tetraploid complementation [138]. 
Other studies showed that Sox2 is also required, not only for normal embryonic development 
and lineage specification but also for successful reprogramming. Embryos that carry a 
homozygous deletion of the Sox2 gene die soon after implantation of the embryo revealing 
the essential role of the regulator [139]. Interestingly, Sox2 requirement is phenotypically not 
manifested until after implantation due to sufficient maternal Sox2 protein in these early days 
of embryonic development [139]. Deeper insight was given by a study that used small 
interfering (si) RNA-mediated depletion of both, maternal and embryonic, Sox2 mRNA at the 
two-cell stage [140]. In vitro observation of embryonic development revealed that these 
embryos arrest at the morula stage and fail to form trophectoderm revealing a major role for 
Sox2 in establishment of the trophectoderm lineage. Interestingly, expression of the 
pluripotency-associated markers Oct4 and Nanog remained unaffected when Sox2 was 
depleted indicating that these three transcription factors exhibit independent functions 
despite of their high connectivity in regards to pluripotency [140]. The role of Sox2 in the 
process of reprogramming has also been investigated and studies showed that endogenous 
expression of Sox2 facilitates the conversion of melanocytes into iPSCs indicating that 
particular cell type are more susceptible to reprogramming than others, dependent on their 
endogenous gene expression signature [141]. 
Knowing that Oct4, Sox2 and Nanog are of individual importance in regards to pluripotency, 
also their direct or indirect interaction is of great interest. Transcription factors generally work 
in a complex interaction system including several different proteins rather than playing an 
isolated role during development and homeostasis. This holds true for the pluripotency-
associated factors Oct4, Sox2 and Nanog, which demonstrate a high degree of complex 
interactions with promoter regions and other proteins. For instance, Sox2 supports 
maintenance of pluripotency in part by regulating Oct4 levels whereas Oct4 can 
heterodimerize with Sox2 showing the interconnected regulatory network [142]. On 
transcriptional level it is known that Oct4, Sox2 and Nanog bind together on their own 
promoters to form an auto-regulatory loop, which stabilizes the pluripotent state (summarized 
in Figure 2). This auto-regulatory circuitry in combination with para-regulatory effects on 
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each of the factors suggests that the three factors function collaboratively to maintain their 
own and each other’s expression. Aside from direct binding to each other’s promoters, these 
three factors often co-occupy their target genes indicating a synergistic role in regulation of 
gene expression. One study using chromatin immunoprecipitation and a hybridization-based 
screening of promoter sequences established a model that includes a subset of active and a 
subset of repressed target genes, which promoters are co-occupied by Oct4, Sox2, and 
Nanog [143]. The active set includes genes encoding factors of chromatin-remodeling and 
histone-modifying complexes as well as genes that directly encode for transcription factors 
such as signal transducer and activator of transcription 3 (STAT3), which themselves are 
known to regulate specific genes [143]. These data indicate that the three key players of 
pluripotency guide a complex gene expression signature and work as a regulatory unit aside 
of their independent functions. 
On protein level, direct interactions are shown for Oct4, Sox2 and Nanog. In ESCs a multi-
protein complex containing Oct4 and Nanog has been identified by iterative 
immunoprecipitation [144]. In addition, Sox2, Oct4 and Nanog do not only associate with one 
another in pluripotent cells, they also cluster together with common transcription factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2  Regulatory interactions between members of the pluripotency-circuit 
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providing further evidence that multiple interacting proteins synergistically control 
pluripotency. For instance, using embryonic stem cells engineered for inducible expression of 
the four reprogramming factors (OKSM), more than 70 proteins that associate with Sox2 in 
ESC were identified [145]. Strikingly, 25 % of these proteins have been shown to be part of 
the Oct4-interactome studied previously [145]. In an Oct4-centered analysis a larger dense 
interaction network was detected, which contains 166 proteins and includes Sall4, Tcfcp2l1, 
Dax1, and Esrrb. The network is not only comprised of transcription factors and chromatin-
modifying complexes that are known to possess roles in self-renewal, but many factors have 
not been previously associated with the pluripotency network [146]. In addition, a 
comprehensive study in murine embryonic stem cells revealed a complex DNA-protein 
interactome of Oct4, Nanog and Sox2. The three transcription factors co-occupy promoters 
of genes, whose translated proteins in turn are present in protein-complexes containing Oct4 
([147], simplified in Figure 2). Sall4, for instance, is a downstream target of all three master 
regulators and was found in the Oct4-centered protein-network purified from mouse 
embryonic stem cells [147]. This further underlines the interconnectivity of regulatory loops 
used by Oct4, Sox2 and Nanog in order to maintain pluripotency. 
Considering the tight interplay between these three master regulators of pluripotency, it is 
plausible that overexpression of one or two transcription factors, for instance in OSKM-
directed reprogramming, re-activates expression of endogenous Oct4, Sox2 and Nanog, the 
products of which in turn contribute to maintenance of their own gene expression guiding the 
cellular state towards pluripotency (reviewed in [148]). 
1.2.4. Dissecting the reprogramming process 
After disproving the dogma of irreversible differentiation, several research groups focused on 
dissecting the molecular and cellular events associated with nuclear reprogramming. Since 
the generation of iPSCs from murine embryonic fibroblasts (MEFs) occurs at a frequency of 
less than 0.1 % and is delayed by omission of c-Myc, it was of interest to reveal molecular 
mechanisms and roadblocks during reprogramming in order to elucidate how cellular identity 
can be reset [137,138,149]. It was demonstrated that reprogramming MEFs is a gradual 
process that requires 15 to 20 days upon transduction of somatic cells with retroviruses 
expressing Oct4, Sox2, Klf4, and c-Myc and results in fully reprogrammed MEF-iPSCs re-
expressing endogenous pluripotency-associated genes including Oct4 and Nanog 
[137,138,150]. When reprogramming is induced by forced expression of Oct4, klf4, Sox2 and 
c-Myc, cells become independent of exogenous factors after ten to 12 days [150,151]. 
Regarding the controversial discussion whether reprogramming is a deterministic/hierarchic 
or a more probabilistic/stoichiometric process, evidence for both theories were found [152]. In 
one study, high-resolution live time–lapse imaging was used to trace the reprogramming 
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process from single donor cells to iPSC-colonies and an early specifying event during 
reprogramming was found to support the idea of a deterministic reprogramming process 
[153]. In contrast, profiling of 48 genes in single cells at various stages during the 
reprogramming process revealed heterogeneous gene expression at early stage of 
reprogramming that is followed by a Sox2-guided deterministic phase [154]. Data from both 
studies suggest a more complex theory of reprogramming by investigating not only 
alterations of mRNA and miRNA expression but also DNA-methylation, chromatin status and 
histone modifications [151]. Hochedlinger et al. revealed that reprogramming is accompanied 
by two deterministic phases at early and late stages of reprogramming, separated by a 
phase of stoichiometric events [151].  
Focusing on the gradual process of changes in gene expression, it is shown that during the 
reprogramming process, MEFs undergo a process called mesenchymal-to-epithelial-
transition (MET) encompassing downregulation of Snai1, a mesenchymal marker, and 
upregulation of E-cadherin [151]. This is confirmed by other studies showing that 
reprogramming is accompanied by transient expression of epithelial markers indicating that 
this conversion of cell fate is not the simple reversion of differentiation [155]. In addition, 
studies reveal that this MET observed during reprogramming is an essential process for 
successful iPSC generation [156,157]. In order to further characterize the transiently 
occurring MET, proteomic analysis of OKSM-induced reprogramming in MEFs was 
performed. An early stage of reprogramming (day 0-3) was identified as the time point of 
changes in protein expression pattern that represent this MET [158]. Further studies revealed 
that expression of epithelial markers and not the MET-conversion itself is the limiting factor to 
successfully induce pluripotency [159,160]. Detailed investigations showed that the 
requirement of E-cadherin expression can be bypassed by N-cadherin expression in order to 
induce MET in mesenchymal cells and restore the ability to acquire induced pluripotency. 
Taken together, these results showed that neither the process of MET nor the expression of 
E-cadherin is required for successful reprogramming. Instead, the adhesion capacity is 
mediated by more than one cadherin which enables reprogramming [161]. 
In addition to the MET process, another study demonstrated that cytoskeletal remodeling is 
essential for reprogramming. The authors identified expression of two kinases, which 
stabilize actin stress fibers in fibroblasts, as barriers for iPSC-generation from murine or 
human fibroblasts [162]. Using a kinome-wide RNAi-based screen, 734 kinase genes were 
targeted by lentivirus-mediated knockdown. Individual knockdowns were investigated 
regarding their effects on iPSC generation using Oct4-driven green fluorescence protein 
(GFP) expression in MEFs. Seven out of 59 kinases, which showed an effect on 
reprogramming, were further characterized and knockdown of the serine/threonine kinases 
 - Introduction -  
- 30 - 
 
Tesk1 and Limk2 was found to promote EMT and disrupt actin filament structures during 
reprogramming [162]. 
In summary, reprogramming is comprised of a variety of different developmental processes 
including MET and cytoskeleton remodeling, and despite intense research many roadblocks 
and involved pathways are still to be elucidated. 
1.2.5. Similarities between malignant transformation and reprogramming 
Both, malignant transformation and reprogramming, lead to acquisition of unlimited self-
renewal. Initial indications of connections between these two processes, which convert the 
functional fate of a cell, were found by identifying regulatory pathways common for both. One 
well-studied pathway involved in tumorigenesis that also plays a crucial role in 
reprogramming is p53-mediated signaling. Functional analyses of several p53-regulated 
genes identified by DNA microarray analyses demonstrated that the p53–p21 pathway 
serves as a barrier not only in tumorigenesis, but also in iPSC-generation [163]. This was 
confirmed by Utikal et al. who disclosed that the acquisition of immortality is a crucial and 
rate-limiting step towards the establishment of a pluripotent state in somatic cells [164]. 
Another pathway that is common between reprogramming and tumorigenesis is the 
metabolic switch in favor of glycolysis. The conversion from oxidative phosphorylation to 
glycolysis despite sufficient oxygen supply, which is observed after malignant transformation 
of cells, is well known as the Warburg-effect ([165], discussed in [166]). Interestingly, 
stimulation of glycolysis promotes, while blockade of glycolytic enzyme activity blunts 
reprogramming efficiency indicating that the metabolic conversion is also essential for the 
reprogramming process [167]. These data indicate that reprogramming and malignant 
transformation use identical mechanisms in order to change the cellular function either 
towards pluripotent characteristics or towards malignant properties. This is further supported 
by several other studies proving a connection between stem cell-associated gene expression 
and tumor initiation or progression, respectively. Oct4, a major pluripotency-associated 
marker, is detected not only in adult human stem cells but also in cultured tumor cell lines 
[168]. In addition, Oct4 is found to be expressed in different breast cancer cell lines in 
contrast to untransformed cell lines indicating a de novo acquisition of Oct4 expression in 
somatic cells after transformation [169,170]. In 2005, Hochedlinger and colleagues 
demonstrate that the activation of Oct4 using a doxycycline-inducible system is sufficient to 
induce dysplastic growths in epithelial tissues in a reversible manner. This suggests that 
aberrant expression of Oct4 is connected to uncontrolled proliferation and malignant 
transformation [135]. 
Oct4 is not the only member of the pluripotency-circuit known to be involved in 
carcinogenesis. In breast cancer cells, different studies showed a correlation between 
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Oct4/Nanog expression and clinical outcome or metastatic potential of cancer cells, 
respectively. Oct4 and Nanog also promote EMT in breast cancer stem cells and are 
associated with poor prognosis for breast cancer patients [171]. Another study showed that 
Nanog is involved in self-renewal and EMT in breast cancer cells supporting the hypothesis 
that these stem cell-associated factors are key players in the EMT and thus involved in 
cancer progression and metastasis [172]. Although overexpression of Nanog in the 
mammary gland of mice is not sufficient to induce breast cancer, it promotes migration and 
invasion of breast cancer cells indicating a major role in metastasis, not in tumor initiation 
[173]. In contrast, when Nanog is ectopically expressed together with Oct4, these 
transcription factors trigger Slug expression and enhance the tumor-initiating capability of 
lung adenocarcinoma cells. This work suggests an important interplay between these stem 
cell factors regarding tumorigenesis and tumor progression [174]. Moreover, Slug promotes 
tumor progression by stimulating Sox2 and Nanog expression in hepatocellular carcinoma, 
further underling the complexity and variety of stem cell maker-pathways that are affected 
during tumorigenesis [175]. 
A study comparing expression of pluripotency-associated genes in samples from cancer 
patients revealed that Sox2 is overexpressed at later stages in several cancers compared to 
early stages. Among others, this was shown for bladder carcinoma, glioma, head and neck 
cancers and breast tumors [176]. In addition, some studies discuss Sox2 and its expression 
as a marker for cell invasion in melanoma. Experimental knockdown of Sox2 in human 
melanoma cell lines possessing high levels of endogenous Sox2 resulted in decreased 
invasion potential in vitro with diminished expression of Mmp3. In addition, analysis of patient 
samples and xenograft melanomas disclosed that Sox2 is co-expressed with Mmp3 in 
regions of stromal infiltration [90]. This indicates a role of Sox2 in invading melanoma cells 
with Mmp3 being a potential mediator of proteolytic invasion during disease progression. 
Using tissue microarray analysis of nevi and melanomas, it was further demonstrated that co-
expression of Sox2 and another neural progenitor cell biomarker, nestin, correlated with 
tumor progression. Moreover, co-expression of Sox2 and nestin labels cells exhibiting a 
rather spindle shape-like cell morphology compared to the epithelioid cell shape of Sox2 
negative cells [177]. 
Another study manifests the link between ESC-like gene expression patterns and tumor 
progression since generally, more aggressive cancer subtypes with a rather de-differentiated 
phenotype demonstrate upregulation of ESC-like genes leading to worse clinical outcome. 
Genes that are activated by Nanog, Oct4 or Sox2, and encode transcription regulators were 
most consistently overexpressed in high-grade breast tumors [178]. These studies support 
the hypothesis that stem cell–like expression signatures observed in several tumors, is 
connected to disease progression. 
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All three members of the circuit of pluripotency are linked to tumor initiation and progression 
(reviewed in [179]) indicating that pluripotency-associated features can be at least in part 
affect different stages of carcinogenesis including malignant transformation, tumor 
maintenance and metastatic spreading. Thus, cancer research can significantly benefit from 
the detailed investigation of reprogramming. 
1.2.6. Reprogramming of cancer cells 
Since studies in reprogramming have revealed strong connections between the modulation 
of pluripotency and cancer, it is of interest to investigate whether reprogramming itself 
influences cancer and its characteristics. A historical study in frogs in 1969 showed that 
triploid tumor cells can be transplanted into activated and enucleated eggs leading to 
formation of swimming triploid tad-poles demonstrating pluripotency [180]. These data 
demonstrated that epigenetic alterations induced by factors present in the oocyte are 
sufficient for turning a tumor genome into that of a normal pluripotent cell that is capable of 
differentiating into different normal tissues. In 2003, a group re-assessed this hypothesis in 
mice and showed that blastocysts derived from medulloblastoma nuclei form post-
implantation embryos with typical cell layers [181]. Another study supporting this hypothesis 
by Hochedlinger and colleagues revealed that a cancer cell can be reprogrammed into ESC-
like cells by nuclear transfer of a malignant melanoma nucleus into an oocyte [182]. In 2011, 
researchers discovered that a tumor cell can be converted into a pluripotent status using just 
the oocyte extract without nuclear transfer further proofing the tremendous effect of 
pluripotency induction on tumor cell-characteristics [183]. 
After the discovery of iPSCs and reprogramming with defined factors, it is of great interest 
whether transcription factor-mediated reprogramming also applies for cancer cells. By now 
several studies have shown successful reprogramming of murine and human cancer cells 
towards a pluripotent stem cell-like cell type using overexpression of the classical Yamanaka 
factors, Yamanaka factors in combination with Nanog and Lin28 [184,185], with three factors 
only (Oct4, Klf4 and c-Myc) [141] or with two factors only [186] depending on the cancer cell-
source. For example, a technical approach by Utikal et al. demonstrated that melanoma cells 
still remain susceptible to transcription factor-mediated reprogramming and that 
endogenously expressed pluripotency-associated factors, i.e. Sox2, facilitate reprogramming 
of these cells [141]. 
After revealing the possibility of cancer cell reprogramming, different studies were performed 
to identify the effects of pluripotency induction on tumor cells. It was shown, that 
reprogramming towards pluripotency reversed the aberrantly deregulated genes in non-small 
cell lung cancer cells via methylation changes and subsequent alteration of transcriptional 
activity. This leads to upregulation of silenced tumor suppressor genes and suppression of 
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oncogene expression indicating that epigenetic modifications can convert cancer-associated 
gene expression into expression patterns of normal cells [184]. In addition, it was shown that 
generation of so-called induced pluripotent cancer cells (iPCCs) from gastrointestinal cancer 
cell lines results in higher sensitivity to chemotherapeutic agents and differentiation-inducing 
treatment [185]. This work is of high interest especially regarding therapeutic challenges and 
drug resistance. 
Investigations on human sarcoma cells showed that they can be reprogrammed and 
subsequently terminally differentiated with abrogation of tumorigenicity [187]. This revealed 
that reprogrammed cancer cells re-assemble all required in vitro criteria for full 
reprogramming towards pluripotency, although promoter methylation analysis discloses that 
cells remain in a de-differentiated state slightly before the mesenchymal stem cell 
differentiation stage. Thus, cancer cells can lose their tumorigenicity without the need to 
completely revert to an embryonic state [187]. Strikingly, they demonstrated that 
reprogrammed cells can be terminally differentiated into mature connective tissue and red 
blood cells and that this differentiation is accompanied with loss of both proliferation and 
tumorigenicity [187]. 
In addition, it was discovered that reprogramming of glioma-derived tumor cells and 
subsequent loss of tumorigenicity in differentiated cells is lineage-dependent. This indicates 
that only an epigenome associated with an alternative developmental lineage can suppress 
malignant behavior. In this study, glioma-derived iPCCs were directed to neuronal cell types, 
which were highly malignant upon xeno-transplantation. In contrast, when differentiated into 
non-neural cell types, sustained expression of reactivated tumor suppressors and reduced 
infiltrative behavior was observed [186]. 
Due to the loss of tumorigenicity in cancer cells upon reprogramming towards pluripotency, 
some researchers claim reprogramming to be a potential clinical application for anti-cancer 
treatment [187]. However, reprogramming in vivo as a therapeutic treatment does not meet 
the needs of clinical applications for obvious reasons, including unlimited self-renewal of 
iPSCs, spontaneous differentiation in vivo and tumor formation. Thus, reprogramming of 
cancer cells so far is not a clinical solution but rather an innovative tool to investigate 
particular cellular functions in order to understand underlying mechanisms in tumorigenesis. 
A recent study disclosed that overexpression of defined transcription factors in cells from a 
glioblastoma tumor resulted in the reprogramming of these cells into the tumor-propagating 
CSC-like cell [188]. This result indicates that tumor cells show divers responses to nuclear 
reprogramming and that this process can be used to establish in vitro systems for more 
detailed analyses of tumor progression including investigation of CSCs.  
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Figure 3  SNAI-zinc finger protein structure 
1.3. SNAI3 and the Snail transcription factor family 
In this final section of the introduction the Snail transcription factor family will be discussed 
with the major focus on SNAI3, the most recent member. 
SNAI3 belongs to the Snail gene family that is firstly identified in drosophila melanogaster 
and consists of three genes: Snai1/Snail, Snai2/Slug and Snai3/Smuc [189]. Today, human 
SNAI1 and SNAI2 are widely accepted to play important roles throughout development and 
disease such as cancer, whereas little is known about the recently discovered third family 
member, SNAI3 [190]. 
1.3.1. Identification and expression of SNAI3 
In mouse, Snail1/Sna, Snail2/Slug, and Snai3/Smuc encode for transcriptional repressors 
that represent a subfamily of Snag zinc finger proteins (reviewed in [191]). All Snai family 
genes are evolutionarily conserved and despite identification of human SNAI1/SNAIL gene 
on chromosome 20ql3 and human SNAI2/SLUG gene on chromosome 8qll decades ago 
[192,193], human SNAI3/SMUC was detected in silico on chromosome 16q24.3 in 2002 for 
the first time [194]. The coding region of the human SNAI3 gene spans nucleotide position 
320214-328221 of human reference genomic contig NT_010404.8 in the reverse orientation 
[194]. 
Using in silico differential expression analyses by listing sources of expressed sequence 
tags, human SNAI3 mRNA was shown to be only present in B cells [195]. However, using in 
vitro and in vivo assays, SNAI3 was further characterized and its function was evaluated in 
mice. Since SNAI3 can be isolated from murine adult muscle, it was named Smuc (Snail-
related in muscle cells) [196]. Functional assays support a potential role for SNAI3 in muscle 
differentiation processes, since overexpression of SNAI3 in myoblasts repressed 
transactivation of muscle differentiation marker Troponin T [196]. 
In situ hybridization analysis at various stages of mouse development disclosed that SNAI3 
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expression cannot be detected until 12.5 days post-coitus (dpc). Its expression was 
exclusively observed in skeletal muscles and thymus at 13.5 and 15.5 dpc and these organs 
remained the major sites of SNAI3 expression until postnatal day two [197]. Thus, analysis of 
SNAI3’s function during embryonic development revealed that it might play a role in 
morphogenesis of skeletal muscles and thymus at a relatively late stage of mouse 
development [197]. However, SNAI3 is not required for normal development in mouse since 
mice lacking SNAI3 show no obvious malformations [198]. 
1.3.2. Structure and molecular function of SNAI3 
Figure 3 shows a schematic overview of all human SNAI transcription factors and their 
protein structure derived from UniProt data using Dog1.0 software [199]. All three 
transcription factors enclose a highly conserved carboxy (C)-terminal region containing four 
to six C2H2-type zinc fingers. This C-terminal region conducts sequence-specific interactions 
with DNA promoters, which comprise the so-called E-box sequence (CAGGTG) [200]. This 
specificity of target sequences is also shown for SNAI3 using electrophoretic mobility shift 
assays [196]. More specific, the 292 amino-acid-long polypeptide SNAI3 competes with basic 
helix loop helix transcription factors for binding DNA at the E-box sequence in a dose-
dependent manner [194–196]. In addition, its non-zinc finger repressor domain is required for 
repressing transcription activity and each SNAI protein possesses an amino terminal SNAG 
(Snail and Gfi-1) domain, that is, at least for SNAI1 and SNAI2, known to interact with 
various histone deacetylases resulting in silencing of target gene expression [196,201,202]. 
1.3.3. Snail/Snai1 and Slug/Snai2 and their role in EMT 
The first member of the snail gene family, Snai1/Snail, was shown to play an important role 
in mesodermal formation during embryogenesis by repressing expression of target genes 
[195,203]. Snai1 is required for successful gastrulation, since Snai1-mutant mice die at this 
stage of development due to defects in EMT and subsequent mesoderm formation [204]. 
Strikingly, it is not the absence of mesoderm formation that leads to ineffective development 
of the organism but rather the inability to downregulate E-cadherin. This repression of E-
cadherin is required for migratory properties of cells and despite mesodermal marker 
expression, i.e. branchury, defective migration leads to abortion of development during 
gastrulation in the absence of Snai1 [204]. These data suggest a major role for Snai1 
regarding cellular movement and adhesion rather than determining mesodermal cell fate. 
Motility and migratory capacities are essential for the EMT process and both Snai1 and 
Snai2 were shown to play a major role in inducing this phenotypic transition in different 
contexts. Using EMT, cells can contribute to formation of many tissues during embryonic 
development but EMT also enables acquisition of invasive properties in epithelial tumors 
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(reviewed in [205]) and thus, genes involved in EMT are potential tumor-promoting targets for 
therapeutic interventions. Therefore, understanding the pathway of inducing SNAI-family 
transcription factors during EMT gives insights into tumorigenesis and especially into 
metastasis formation. Although the most popular function Snai1 and Snai2 are associated 
with is EMT induction, some developmental and pathological characteristics prove EMT-
independent functions including survival via attenuation of cell cycle and resistance to pro-
apoptotic stimuli upon growth factor deprivation or DNA-damage [206–208].  
1.3.4. SNAI3 in cancer 
The role of SNAI3 in pathological conditions has not been investigated in detail. The location 
of SNAI3 on chromosome 16q24.3 comprises a region that is affected in different types of 
cancer including hepatocellular carcinoma and ovarian cancer [194]. Also, preliminary 
expression screening in silico demonstrated its messenger expression in lung epidermoid 
carcinoma, germ cell tumors and skin cutaneous melanoma [194]. These data indicate a 
potential role for SNAI3 in tumor formation, maintenance or metastasis and in this study its 
role in melanoma progression is evaluated. 
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2. Objectives 
Despite vast investigations of the reprogramming process, its impact and use for cancer 
research is far less elucidated. Some studies have shown that cancer cells can be converted 
into a pluripotent state and that this is accompanied by altered cellular function, including 
proliferation and tumor formation capacity. However, cellular alterations have only been 
assessed after complete conversion of tumor cells into the pluripotent state, which leaves the 
de-differentiation stages during reprogramming aside. 
This project aims to dissect the process of reprogramming murine melanoma cells towards a 
pluripotent state in order to investigate the impact of directed de-differentiation on melanoma 
cells’ function. In order to establish a platform that can be used for this approach, I first aim to 
convert murine melanoma cells into a pluripotent state. The main part of this project 
comprises the stepwise analysis of reprogramming melanoma cells at defined time points. 
Cellular function including migration and invasion will be investigated since especially in 
melanoma, de-differentiation is linked to higher metastatic potential. Thus, I aim to clarify 
o whether or not partial reprogramming of melanoma cells is a stable and reproducible 
process 
o if proliferation and/or invasion capacities changes during the process of 
reprogramming 
o whether this in vitro model of partial reprogramming can be used to identify novel 
target genes with clinical relevance for melanoma progression 
 
In summary, I aim to establish a novel in vitro system with potential to mimic metastasis-
promoting events in melanoma cells in order to identify novel genes that are connected to 
invasive properties and might serve as biomarkers for melanoma progression. 
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3. Materials and methods 
3.1. Materials 
3.1.1. Reagents 
Product description Company Branch 
Agarose NEEO Ultra Qualität Carl Roth Karlsruhe, Germany 
AmershamTM ECLTM Prime 
Western Blotting Detection 
Reagent 
GE Healthcare UK Limited Little Chalfont 
cOmplete Mini - Protease 
Inhibitor Cocktail Tablets in 
EASYpacks 
Roche Diagnostics 
Corporation 
Roche Applied Science 
Mannheim, Germany 
DAKO mounting medium DAKO Agilent Technology Hamburg, Germany 
Dimethylsulfoxide (DMSO) Dimethylsulfoxide (DMSO) Dimethylsulfoxide (DMSO) 
NuPAGE® LDS Sample 
Buffer 
Invitrogen. ® Life 
Technologies Darmstadt, Germany 
NuPAGE® MES SDS 
Running Buffer 
Invitrogen. ® Life 
Technologies Darmstadt, Germany 
Phusion® High-Fidelity DNA 
Polymerase  New England Biolabs GmbH  Ipswich, MA, USA 
Propidium Iodide Sigma Aldrich Steinheim, Germany 
RIPA Buffer Sigma Aldrich Steinheim, Germany 
Rotiphorese® gel 30 Carl Roth Karlsruhe, Germany 
Skim milk powder Fluka analytical Steinheim, Germany 
TMED (C6H16N2) Carl Roth Karlsruhe, Germany 
Tween20 Applichem Darmstadt, Germany 
 
3.1.2. Materials 
Product description Company Branch 
Whatman chromatography 
paper GE Healthcare Buckinghamshire, UK 
Immobilon-P Transfer 
Membrane Pore size 
0.45 µM 
Millipore Schwalbach, Germany 
NuPAGE® Novex® 4-12 % 
Bis-Tris Mini Gels 
Invitrogen. ® Life 
Technologies Darmstadt, Germany 
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3.1.3. Antibodies  
Product description Working dilution Company  Branch 
anti-Ki67 antibody 
(ab15580) 1:400 Abcam Cambridge, UK 
anti-mouse HRP 
labeled 1:10,000 (IB) 
Jackson 
ImmunoResearch 
Inc. 
Suffolk, UK 
anti-Nanog ab80892 1:500 (IF) Abcam Cambridge, UK 
anti-rabbit HRP 
labeled 1:10,000 (IB) 
New England Biolabs 
GmbH  Ipswich, MA, USA  
α-actinin Antibody sc-
17829 1:10,000 (IB) 
Santa Cruz 
Biotechnology 
Heidelberg, Germany 
Anti-SOX2 1:100 Novus Biologicals Cambridge, UK 
Anti-OCT4 1:500 Abcam Cambridge, UK 
Anti-S100B 1:400 Abcam Cambridge, UK 
Anti-SNAI3 (IHC) 1:400 Sigma-Aldrich Steinheim, Germany 
Anti-SNAI3 (western) 1:1000 Abgent Maidenhead, UK 
 
3.1.4. Cell culture materials 
Product description Company  Branch 
2-Mercaptoethanol Gibco® Life Technologies Darmstadt, Germany 
Alamar Blue® AbD Serotec Puchheim, Germany 
Cholera Toxin Sigma-Aldrich Steinheim, Germany 
DMEM AQmedia Sigma-Aldrich Steinheim, Germany 
Doxycyline Sigma-Aldrich Steinheim, Germany 
Dulbecco‘s Phosphate 
Buffered Saline Sigma-Aldrich Steinheim, Germany 
ES-Cult™ Fetal Bovine 
Serum for Maintenance 
STEMCELL Technologies 
SARL Cologne, Germany 
Fetal Calf Serum (FCS) Biochrom Berlin, Germany 
X-tremeGENE Transfection 
Reagent  Roche Mannheim, Germany 
Glutamax DMEM Sigma-Aldrich Steinheim, Germany 
Non-essential amino acids Sigma-Aldrich Steinheim, Germany 
Penicillin Streptomycin Sigma-Aldrich Steinheim, Germany 
Recombinant human  
TGFβ-1 
PeproTech Rocky Hill, NJ USA 
Sodium Pyruvate Sigma-Aldrich Steinheim, Germany 
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Trypan Blue solution Sigma-Aldrich Steinheim, Germany 
Trypsin Sigma-Aldrich Steinheim, Germany 
12-0-tetradecanoyl phorbol 
acetate (TPA) Sigma-Aldrich Steinheim, Germany 
 
3.1.5. Cell lines 
 Cell line Source Authentification Origin Mutation 
H
um
an
 
SK Mel 28 ATCC 100 % (Multiplexion, Heidelberg Germany) 
Malignant 
Melanoma 
BRAF 
V600E 
SK Mel 30  100 % (Multiplexion, Heidelberg Germany) Melanoma 
NRAS 
Q61R 
MeWo Ballotti lab, Nice 
100 % (Multiplexion, 
Heidelberg Germany) 
Malignant 
Melanoma WT/WT 
A375 ATCC 100 % (Multiplexion, Heidelberg Germany) 
Malignant 
Melanoma 
BRAF 
V600E 
Fibroblasts Lab intern NA Human skin biopsy NA 
M
ur
in
e 
Ret2 Prof. Umansky NA Ret mouse NA 
HCmel12 Prof. Tüting 
Yes 
(individual library at IDEXX 
BioResearch) 
HC/mel mouse 
HGF/ 
CDK4R24
C  
HCmel12-
iPCCs -  
100 % identity of HCmel12 
(individual library at IDEXX 
BioResearch) 
HC/mel mouse 
HGF/ 
CDK4R24
C  
HCmel17 Prof. Tüting 
Yes 
(individual library at IDEXX 
BioResearch) 
HC/mel mouse 
HGF/ 
CDK4R24
C 
HCmel17-
iPCCs -  
100 % identity of HCmel17 
(individual library at IDEXX 
BioResearch) 
HC/mel mouse 
HGF/ 
CDK4R24
C  
MEF Lab intern NA C57B/6J mouse none 
 
3.1.6. Plasmids 
Plasmids Used for Source  
pLU-EF1aL-rtTA3-iCherry Partial reprogramming The Wistar Institute 
pLX304-human SNAI3 SNAI3 overexpression Genecopoeia 
pLX304-control SNAI3 overexpression control Genecopoeia 
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3.1.7. Kits 
Product description Company  Branch 
Alkaline Phosphatase 
Staining Kit #II00-0055 
Stemgent 
 
Cambridge, USA 
ARCTURUS PicoPure RNA 
Isolation Kit #KIT0204 Life Technologies Darmstadt, Germany 
BD Mouse Pluripotent Stem 
Cell Transcription Factor 
mAnalysis Kit 
BD (Becton, Dickinson and 
Company) Heidelberg, Germany 
CytoSelect™ 24-Well Cell 
Migration and Invasion 
Assay 
Cell Biolabs, Inc.  
First Strand cDNA Synthesis 
Kit #K1612 
Fisher Scientific Germany 
GmbH Schwerte , Germany 
Pierce BCA protein assay kit ThermoScientific Karlsruhe, Germany 
RevertAid RT Kit ThermoScientific Karlsruhe, Germany 
RNase-free DNase set Qiagen Hilden, Germany 
RNeasy Mini Kit Qiagen Hilden, Germany 
Sybr®Green PCR mastermix Applied Biosciences Warrington, UK 
 
3.1.8. Devices 
Product description Company  Branch 
AB 7500 Real Time PCR 
machine 
Applied Biosciences ® Life 
Technologies Darmstadt, Germany 
BD LSRFortessa™ cell 
analyzer BD Biosciences™ Heidelberg, Germany 
ImageQuant LAS 4000 GE Healthcare Life Sciences " UK Limited Little Chalfont 
Nanodrop Spectophotometer 
ND-1000 
Peqlab Biotechnologie 
GmbH 
Erlangen, Germany 
Nikon Eclipse Ti 
Fluorescence microscope Nikon Düsseldorf, Germany 
Nikon Eclipse TS100 Nikon Düsseldorf, Germany 
Tecan infinite F200 PRO Tecan Crailsheim, Germany 
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3.1.9. Solutions 
 Description Components  
Im
m
un
ob
lo
tti
ng
 
Blocking buffer 
5 % Skim milk powder in 
Washing Buffer 
Washing Buffer 
0,02 % Tween 20 
1x TBS  
Transfer buffer 
 
39 mM Glycin  
48 mM Tris  
SDS (20 %)   
dH2O 
RIPA buffer 1x cOmplete Mini (Roche) 
 
3.1.10. Software 
Product description Source 
7500 Software v.2.0.6 Life Technologies, Darmstadt, Germany 
ApE University of Utah 
Chipster Chipster Open source 
FlowJo 7.6.5 FlowJo Enterprise 
ImageJ NIH, USA 
Mendeley Mendeley Ltd., UK 
NIS-Elements Nikon 
Prism 5.0 GraphPad Software, Inc. USA 
 
3.1.11.  Online database 
Product description Source 
Human Protein Atlas http://www.proteinatlas.org/ 
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3.2. Methods 
3.2.1. Cell culture 
HCmel12 and HCmel17 cell lines were cultured in dulbecco’s modified eagle’s medium 
(DMEM) supplemented with 20 % FCS, 1 % penicillin (100 units/ ml) and streptomycin 
(100 µg/ ml), 1 % natriumpyruvat (100 mM), 1 % non-essential amino acids solution (10 mM), 
0.01 % HEPES (1 M), 0.75 % β-mercaptoethanol, hereafter referred to as Mel medium. 
Ret2 cells were cultured in RPMI supplemented with 10 % FCS, 1 % penicillin (100 units/ ml) 
and 1 % streptomycin (100 µg/ ml). 
MEFs and all human cell lines were cultured in DMEM supplemented with 10 % FCS, 1 % 
penicillin (100 units/ ml) and streptomycin (100 µg/ ml), 1 % non-essential amino acids 
solution (10 mM) and 0.75 % β-mercaptoethanol, hereafter referred to as MEF medium. 
Human fibroblasts were immortalized using transduction with SV40 and cultured for more 
than 5 passages before they were used for experiments. 
All pluripotent cells were cultured in KnockOut™ DMEM supplemented with 10 % ES-FCS, 
1 % glutamine, 1 % penicillin (100 units/ ml) and streptomycin (100 µg/ ml), 1 % non-
essential amino acid solution and 100 U/ ml murine leukemia inhibiting factor (LIF), hereafter 
referred to as mESC medium. Established pluripotent cells were cultured on a layer of post-
mitotic feeder cells (see section 3.2.5 for preparation) and splitted every other day using 
trypsin to generate single cell suspension. 
MEF-conditioned mESC medium was generated by culturing MEFs (culture passage < 5) in 
mESC medium and medium was harvested every 12 hours. 
All cell lines were cultured in a humidified incubator with 5 % CO2 and 95 % air. 
3.2.2. Production of lentiviral particles 
For production of infectious lentiviral particles, HEK293T cells were transfected with the 
target vector in combination with the packaging plasmids VSVG and Δ8.9 using Fugene 
(Roche) according to the manufacturer’s protocol and supernatant was discarded 12 h after 
transduction. Viral supernatant was harvested 24 h, 36 h and 48 h after transfection and was 
directly used for transduction of target cells, or centrifuged at 13.500 rpm 5 h (4°C) and 
stored as concentrated virus, respectively. 
3.2.3. Transduction with lentiviral particles 
Cells were seeded with 40-50 % confluence and incubated for 12-24 h to fully attach. 
Medium was changed and virus added (500 µl – 1 ml supernatant or 5 µl concentrated virus, 
respectively) in the presence of 10 µg/ ml polybrene under S2 conditions. After 24 h cells 
were transduced again as described above before transduction was stopped after 48 h total 
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by washing cells three to five times with PBS. Cells were cultured in regular medium for at 
least 12 h to let them recover before performing further experiments. 
3.2.4. Blasticidin selection 
Cells transduced with a plasmid containing a 
blasticidin cassette were selected with defined 
blasticidin concentrations optimized for each cell 
line. For optimization, non- transduced cells 
were seeded in 12-well plates at 50 % 
confluence and blasticidin was added in six 
different concentrations including a negative 
control without blasticidin (50, 17, 10, 5, 2.5 and 
0 ng/ ml). Optimized selection concentration was 
defined as the concentration killing all cells after 
three days of selection (Table 1).  
 
 
3.2.5. Extraction of murine embryonic fibroblasts and feeder preparation 
Mouse embryos from Bl/6 mice were dissected between 12.5 to 13.5 days postcoitum into 10 
to 20 ml sterile PBS in a 100-mm tissue culture dish. Under sterile conditions, heads of 
embryos were removed using sterile scalpels. After transfer of the embryos to a clean 100-
mm tissue culture dish containing sterile PBS, embryos were dissected manually into little 
pieces using scalpels. Embryos were dissociated by aspirating into a 10-ml syringe through a 
16-G needle and incubated in trypsin/EDTA solution to 10 to 20 min in a 37°C incubator. 
After neutralization of EDTA/Trypsin solution with MEF medium, large tissue pieces were 
removed and cell suspension was centrifuged for 5 min at 1000 × g. Cells were plated on 
150 mm2 tissue culture plates and grown until confluent (2 to 5 days). For expansion, 
fibroblasts were plated on five to ten 75 cm2 flasks and when confluent (3 to 5 days) cells 
were frozen with 1x106 cells per aliquot in freezing medium. For direct use as feeder cells, 
MEFs were treated with mitomycinC for 4-5 h with a concentration of 8 µg/ ml. For storage, 
feeder cells were frozen in regular freezing medium. 
  
Cell line Concentration 
(µg/ ml) 
HCmel17-M2 17 
Ret2 10 
MEFs 10 
Hepa 1.6 5 
A375 5 
Mewo 5 
SKmel28 10 
SKmel30 10 
Table 1 Blasticidin selection 
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3.2.6. Reprogramming (Stemcca and Stemcca-blasticidin) 
In order to reprogram cells, a doxycycline-inducible polycictronic lentiviral vector encoding for 
Oct4, Sox2, Klf4 and c-Myc (Stemcca) was used in combination with a lentiviral vector 
encoding for the constitutively active M2 reverse tetracycline controlled transactivator (M2) as 
described previously by Sommer et al. (Suppl. Figure 1a, [209]). One day after the 
transduction, mESC medium containing doxycycline with a concentration of 1 µg/ ml was 
added to induce transgene expression. Fresh mESC medium supplemented with doxycycline 
was added every other day until iPSC colonies developed. 
To establish fully reprogrammed induced pluripotent stem cells (iPSCs) or induced 
pluripotent cancer cells (iPCCs), colonies were picked, single cell suspensions were 
generated and transferred into dishes coated with dense feeder cells. Picked iPSCs/iPCCs 
were cultured on feeder cells in mESC medium without doxycycline and were replated until 
stable colonies could be passaged by trypsinization and single cell suspension. Stable 
iPSCs/iPCCs were used for further experiments. 
For partial reprogramming, cells were transduced with a doxycycline-inducible polycictronic 
lentiviral vector encoding for Oct4, Sox2, Klf4 and a blasticidin resistance gene (Stemcca-
blasti) in combination with a lentiviral vector encoding for the constitutively active M2 coupled 
to mCherry (obtained from the Wistar Institute, [210]). For producing the Stemcca-blasti 
vector, two DNA fragments were generated by overlapping PCRs. One fragment consisting 
of the complementary DNA (cDNA) of murine Sox2 coupled to the N-terminal part of the E2F 
protein was amplified form the Stemcca vector [210]: 
PrimerA: GGTATCGTACATATGATGTATAACATGATGGAGACGGAGCTGAAG, 
primerB:TTTCAACATCGCCAGCGAGTTTCAACAAAGCGTAGTTAGTACATTGCCCACTAC
CCATGTGCGACAGGGGCAGTGTGCCGTTAATGGCCG. 
The second fragment containing the cDNA of the blasticidin-S-deaminase (blasticidin) 
coupled to the C-terminal region of the E2A protein was amplified from a blasticidin 
selectable, modified Tet-O-cMyc-IRES-GFP vector, kindly provided by Christof von Kalle, 
NCT Heidelberg: 
PrimerC: 
GCTGGCGATGTTGAAAGTAACCCCGGTCCTATGAAGACCTTCAACATCTCTCAGC, 
primerD: GGTTTATCGATTTAGTTCCTGGTGTACTTGAGGGGGAT. 
To obtain the Sox2-E2F-blasticidin fusion fragment, a PCR was carried out under the 
following conditions: initial denaturation at 98°C for 1 min followed by 35 cycles of 98°C for 
10 s, 50°C for 15 s, and 72°C for 45 s, followed by a 5 min at 72°C (primerA, primerD). The 
resulting fragment (Sox2-E2F-blasticidin) was gel-purified, NdeI- and ClaI-digested and 
inserted by directional cloning into the NdeI- and ClaI-digested Stemcca vector backbone 
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downstream of the internal ribosome entry site (IRES) element. All cloning procedures were 
performed with the help of Dr. Daniel Novak. 
Cells were subjected to antibiotic selection starting at day three after transgene expression. 
Reprogramming process was stopped after indicated days and cells were used for further 
analysis in the absence of doxycycline. 
3.2.7. Alkaline phosphatase staining 
Cells were stained with the Alkaline Phosphatase Staining Kit II (Stemgent) according to the 
manufacturer’s protocol. Briefly, cells were fixed and incubated with alkaline phosphatase 
substrate containing solution and the generation of red alkaline phosphatase-positive 
colonies was determined. 
3.2.8. RNA extraction and cDNA synthesis 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) or the ARCTURUS PicoPure 
RNA Isolation Kit (Life Technology), respectively, according to the manufacturer’s protocol. 
Briefly, cells were lysed and RNA was purified with a column-based system. After washing 
and on-column DNAse treatment, RNA was eluted from the column using nuclease-free 
water. Concentration and integrity were measured using NanoDrop 1000 Spectrophotometer 
V3.7. 
500 ng RNA was used to generate cDNA using the first strand cDNA synthesis kit according 
to the manufacturer’s protocol. For all experiments, oligo-dT-Primers were used for cDNA-
synthesis including the optional incubation step at 65°C and cDNA was diluted 1:10 in 
nuclease-free water before used for quantitative PCR. 
3.2.9. Quantitative PCR (qPCR) 
PCR was performed using SYBR Green in combination with the Applied Biosystems® 7500 
Real-Time PCR System (Life Technologies) according to manufacturer’s protocols. Used 
primer sequences are listed in Table 2. Expression of target genes was normalized to the 
housekeeping gene Gapdh after all cells were tested for low inter-sample-variance in Gapdh 
expression (≤2 cycles, data not shown). All primers were validated and primers with 
amplification efficiencies between 80 – 120 % were defined as functional. All samples were 
analyzed in technical triplicates and data was processed using the 7500 Software and the 
delta(delta(Ct)) method. Graphs were generated using Prism Software and error bars show 
variance as 95 % confidence interval calculated in 7500 Software. 
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Table 2 RT-Primers 
 
  
 Amplified 
gene Primer forward Primer reverse 
M
ur
in
e 
Oct4 TAGGTGAGCCGTCTTTCCAC GCTTAGCCAGGTTCGAGGAT 
Sox2 TTAACGCAAAAACCGTGATG GAAGCGCCTAACGTACCACT 
Nanog TTGCTTACAAGGGTCTGCTACT ACTGGTAGAAGAATCAGGGCT 
Ssea1 ACGGATAAGGCGCTGGTACTA GGAAGCCATAGGGCACGAA 
Cdh2 CGTCCACCTTGAAATCTGCT AAGGACAGCCCCTTCTCAAT 
Plastin3 TGGAGAGGGTCAGAAAGCAAA AATCCACAACCGCCAAACTG 
Plat AGTTCCTGCTGGGTGCTGTC CGGGGACCACCCTGTATGTT 
Sall4 TCCAACATTTATCCGAGCACAG TGGCAGACGAGAAGTTCTTTC 
Snai1 CACACGCTGCCTTGTGTCT GGTCAGCAAAAGCACGGTT 
Snai2 TGGTCAAGAAACATTTCAACGCC GGTGAGGATCTCTGGTTTTGGTA 
Snai3 CACTGCCACAGGCCGTATC CTTGCCGCACACCTTACAG 
Sparc CCAGGCAAAGGAGAAAGAAG TTCAGACCGCCAGAACTCTT 
Twist1 CCCACCCCACTTTTTGACGA GGGATGCCTTTCCTGTCAGT 
Mitf CCAACAGCCCTATGGCTATGC CTGGGCACTCACTCTCTGC 
Wnt5a CTGGCAGGACTTTCTCAAGG CTTCTAGCGTCCACGAACTCC 
Gapdh TGTGAGGGAGATGCTCAGTG TGTTCCTACCCCCAATGTGT 
Fst GAGCAAGGAAGAGTGTTGCAG CTCACACGTTTCTTTACAAGGGA 
H
um
an
 
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC 
18S GAGGATGAGGTGGAACGTGT TCTTCAGTCGCTCCAGGTCT 
SNAI1 GAGGCGGTGGCAGACTAG GACACATCGGTCAGACCAG 
SNAI2   
SNAI3 GGAGACGCAGAGAGAAATCAAT ACCTCGCTGACTTCCAAGG 
CD271 CGACAACCTCATCCCTGTCT GCTGTTCCACCTCTTGAAGG 
DCT GGTTCCTTTCTTCCCTCCAG CCAACAGCACAAAAAGACCA 
MITF GCTCACAGCGTGTATTTTTCC TCTCTTTGGCCAGTGCTCTT 
TYRO TTGTACTGCCTGCTGTGGAG CAGGAACCTCTGCCTGAAAG 
TRP1 AGCAGTAGTTGGCGCTTTGT TCAGTGAGGAGAGGCTGGTT 
CDH2 CTCCTATGAGTGGGAACAGGAACG TTGGATCAATGTCATAATCAAGTGCTGTA 
CDH1 ATTCTGATTCTGCTGCTCTTG AGTAGTCATAGTCCTGGTCTT 
ZEB2 TCCAGAAAAGCAGTTCCCTTC CACACTGATAGGGCTTCTCG 
ZEB1 AGCAGTGAAAGAGAAGGGAATGC GGTCCTCTTCAGGTGCCTCAG 
- Materials and methods - 
- 48 - 
 
3.2.10. Immunoblotting 
Proteins were extracted using radioimmunoprecipitation assay (RIPA) buffer (Invitrogen) 
including complete protease inhibitor cocktail (Roche). Protein yield was measured using the 
bicinchoninic acid (BCA) method (Thermo Scientific) prior to protein separation on 4-12 % 
Bis-Tris pre-cast polyacrylamide gels (Invitrogen) for 90 min at 150 V according to the 
manufacturers’ protocol. Proteins were blotted to methanol-activated PVDF membranes for 
12 h at 33 V and subsequently blocked for 1 h in 5 % BSA in PBS. After incubation with 
primary antibodies in blocking buffer over night at 4°C and 3 washing steps with TBST (each 
lasting at least for 10 min), secondary antibodies against either mouse- or rabbit-IgG labeled 
with horse-radish-peroxidase were incubated for 1-2 h at RT. After 3 additional washing 
steps signals were visualized using ECL™ Western Blotting Detection Reagents (GE 
Healthcare) according to the manufacturers’ protocol and the gel imaging system Image 
QuantTM LAS 4000 assuring to avoid detection of saturated signals. Quantification of proteins 
was performed using ImageJ. 
3.2.11. Immunocytochemistry 
Seeded cells were washed with PBS, fixed for 30 min using 4 % PFA. After several washing 
steps with PBS, unspecific binding sites were blocked with 2.5 % BSA in PBS, before cells 
were incubated with primary antibody. For not directly labeled primary antibodies, additional 
washing with PBS and incubation with a fluorescence-labeled secondary antibody followed. 
Cells were washed with PBS and nuclei were stained with PBS containing 1 µg/ mL of DAPI 
for 3 min. After mounting samples with DAKO mounting medium cells were analyzed using a 
fluorescence microscope (Nikon). 
3.2.12. Flow cytometry 
Induced pluripotent cells are generally cultured on a layer of post-mitotic MEFs as feeder 
cells. In order to reduce the feeder cell contamination in FACS, single cell suspension of 
pluripotent cells and feeder cells was cultured on a non-coated cell culture plate for 90 min. A 
portion of feeder cells attaches to the plate but pluripotent cells do not attach so that this 
“preplating” is used to enrich for pluripotent cells prior to FACS analysis. The remaining 
single cell suspension of reprogrammed cells was subjected to antibody staining using the 
Mouse Pluripotent Stem Cell Transcription Factor Analysis Kit (BD) according to the 
manufacturer’s protocol. Briefly, cell suspension was fixed and stained by incubation with 
directly labeled antibodies against the target markers Oct4, Sox2 and Nanog. After 
incubation with primary antibodies cells were washed and resuspended in PBS containing 
2 % FCS. Acquisition was performed using the BD LSRFortessa™ cell analyzer with 
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FACSDiva software with dead cell exclusion based on scatter profile (Suppl. Figure 1b). 
FlowJo7.6.5 software (Tree star) was used to analyze at least 100,000 events. 
3.2.13. Proliferation assay 
Cells were seeded in triplicates into black 96-well plates. After 72 h, medium was removed, 
10 % Alamar Blue REDOX indicator dye (AbD Serotec) in medium was applied. 
Fluorescence was measured with excitation wavelength at 530-560 nm and emission 
wavelength at 590 nm after 4 h using the Tecan Infinite® 200 PRO plate reader. 
Fluorescence intensity was normalized to wells containing 10 % Alamar Blue REDOX 
indicator dye in medium only. 
3.2.14. Migration and invasion assays 
For all experiments regarding partial reprogramming, invasion capacity was assessed in vitro 
with the CytoSelect™ 24-Well Cell Migration and Invasion Assay (Cell Biolabs, Inc.) 
according to the manufacturer’s protocol. Briefly, cells were seeded in starvation medium on 
top of a well containing an artificial basal membrane as a separation to FCS containing 
medium. After 24 h of incubation in a normal incubator cells that migrated through the 
membrane were detached and lysed with a lysis solution containing a fluorescent dye. 
Fluorescence emission correlates with number of cells and could be used to compare 
invasion potential of different cells. 
For all experiments performed with human melanoma cell lines, migration and invasion 
potential was determined using the Cultrex® 96 Well BME Cell Invasion Assay (©2008, 
Trevigen, Inc.) according to the manufacturer’s protocol. Briefly, cells were starved in serum-
free MEF medium and transwell-chambers were coated with 0.1x basal membrane 
equivalent (BME) coating solution. After 24 h, 1x105 cells per well were seeded on coated 
(invasion) and non-coated (migration) wells. After 24 h, cells that migrated into the bottom 
chamber were lysed and stained with a fluorescent dye. Fluorescence was measured at 
485 nm excitation and 520 nm emission, respectively. Relative migratory and invasive 
potential was determined by comparing relative fluorescence units in order to cross-compare 
between different cell lines. 
3.2.15. Whole genome expression array 
All cells used in the hybridization-based whole genome expression microarray were cultured 
in mECS medium for seven days before extracting RNA to avoid medium-related alterations 
in gene expression. Total RNA extracted using the ARCTURUS® PicoPure® RNA Isolation 
Kit (Life Technology) was sent to the microarray unit of the DKFZ Genomics and Proteomics 
Core Facility who provided the Illumina expression profiling using whole genome BeadChip® 
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Figure 4  Tissue microarray analysis 
Sentrix arrays (mouseWG-6 v2). Differentially expressed genes were identified using 
Chipster v2.12.0. After quantile normalization of raw data using the Illumina normalization in 
Chipster, differentially expressed genes were compared between groups with indicated tests 
stated in figure legends. P-value cutoff was chosen with 0.05 if not otherwise indicated. Gene 
lists extracted after testing were imported into MetaCore™ Data-mining and pathway 
analysis (Thomson Reuters) for gene set enrichment analysis. 
3.2.16. Tissue microarray analysis 
All analyses involving human melanoma tissues were carried out according to the principles 
of the Declaration of Helsinki and were approved by the Medical Ethics Committee of the 
Medical Faculty Mannheim, University of Heidelberg. 37 melanocytic nevi and 26 primary 
melanomas were included in the 
tissue microarray (TMA) used in 
this study. TMA was generated 
at the core facility of the National 
Center for Tumor Diseases 
(NCT), Department of Pathology, 
University of Heidelberg. Each 
sample was included in 
duplicates to the TMA. Before 
TMA was analyzed, visualization 
of melanoma cells was 
performed by staining against 
S100B (Abcam). 
Two blinded individuals applying 
a quantity/intensity- based IHC 
scoring system, which is 
displayed in Figure 4, performed 
scoring of tissue microarrays. 
3.2.17. Immunohistochemistry 
Tumors, which developed in vivo in NOD/SCID, C57B/6, or NSG mice, as well as human 
tissue from melanoma patients, were fixed in 4 % paraformaldehyde (PFA) for 24 h and were 
embedded in paraffin. 5 µm paraffin tissue sections were stained with hematoxylin and eosin. 
Additional staining against Ki67 (Abcam) or Snai3 (Sigma-Aldrich) was performed as 
indicated in figure legends. 
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TMA-slides were stained with indicating antibody (1:100) overnight. After washing with tris-
buffered saline supplemented with tween-20 (0.05 %), slides were incubated with secondary, 
antibody (Dako EnVisionTM + System-HRP) for 60 min. After 15 min incubation with AEC 
and additional washing steps, samples were counterstained with hematoxylin and stabilized 
with mounting medium (Dako S3025) for storage and analysis. 
All histological stainings were performed at the University Medical Center Mannheim with the 
help of Sayran Arif-Said. 
3.2.18. Mouse experiments 
After harvesting iPCCs, they were washed with PBS to remove FCS and medium 
supplements. Cells were resuspended in 100 µl – 300 µl PBS and cell suspensions were 
injected subcutaneously into both flanks of non-obese diabetic/severe combined 
immunodeficient (NOD/SCID) for teratoma assays or into non-obese diabetic/severe 
combined immunodeficient interleukin-2 receptor-γ chain null (NSG) mice for partially 
reprogrammed cells, respectively. Tumor development was observed and mice sacrificed by 
cervical dislocation whenever tumor size reached 1 cm (multiple tumors) or 1.5 cm (single 
tumors), respectively. Mice were sacrificed after 4 months the latest even without developing 
a tumor. Tumors were excised, fixed in 4 % PFA for 24 h and stored in PBS until they were 
embedded in paraffin for histological analysis. 
For intravenous injections, single cell suspensions were washed once with PBS and filtered 
through a 40 µm-pore cell strainer. 2x105 cells in 200 µl PBS were injected into the tail vein 
of C57BL/6 or NSG mice and mice were sacrificed 6 weeks after injections. Lungs were 
excised and fixed in Bouin’s solution for 24 h. Lungs were stored in PBS until they were 
embedded in paraffin for hematoxylin and eosin (H&E) staining and histological analysis. 
All animal experiments were conducted at the animal facility of the DKFZ (Heidelberg, 
Germany) in adherence to the standards of the German law for the care and use of 
laboratory animals.  
3.2.19. Statistical analysis 
Tests for all data except microarray data were performed using GraphPad Prism version 5.00 
(2007) with indicated tests. Significance in two-tailed t-tests was assumed for p≤ 0.05 (*), p≤ 
0.01 (**) or p≤ 0.001 (***), respectively. 
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4. Results 
Reprogramming of cancer cells towards pluripotency provides an innovative tool to 
investigate cancer-associated processes from a novel perspective. Although reprogramming 
of cancer cells has been investigated using different cancer cell types, all induced alterations 
have only been assessed after complete conversion of tumor cells into the pluripotent state, 
which leaves the different stages during reprogramming aside. I established a novel in vitro 
model of partially reprogrammed melanoma cells that mimic the phenotype switch from 
highly proliferative, non-invasive to slowly proliferative, highly invasive cells.  
The first section of this study describes the establishment of several assays that were used 
to evaluate pluripotency in reprogrammed cells. MEFs were reprogrammed via lentiviral 
transduction with defined transcription factors and subjected to gene expression analysis and 
in vitro differentiation. Next, two murine melanoma cell lines were reprogrammed and 
different assays were used for pluripotency confirmation including in vivo generation of 
teratomas. In the third section, the process of reprogramming melanoma cells is dissected by 
analyzing partially reprogrammed cells regarding their cellular characteristics. 
4.1. Establishing different assays to confirm pluripotency in 
reprogrammed somatic cells 
In order to establish the protocol for reprogramming somatic cells towards full pluripotency, 
MEFs were reprogrammed and subjected to a variety of pluripotency-validating assays. 
Figure 5 shows a schematic overview of the technical set-up. MEFs were seeded in MEF 
medium and transduced with a polycistronic lentiviral construct encoding for Oct4, Sox2, Klf4 
and c-Myc under the control of a doxycycline-inducible promoter (Stemcca-vector, 
Suppl. Figure 1a), together with a lentiviral vector encoding the constitutively active M2 
reverse tetracycline controlled transactivator (M2). As a negative control, cells were 
transduced with M2 only in order to exclude that observed effects were due to the expression 
of the reverse transactivator or the presence of doxycycline. After transduction, culture 
conditions were changed from MEF medium to MEF-conditioned mESC medium and 
transcription of exogenous genes was induced by doxycycline administration. Cells were 
further cultured under stem cell promoting conditions (MEF-conditioned mESC medium) in 
the presence of doxycycline.  
Figure 6a illustrates the continuous morphological change from a 2-dimensional monolayer 
of fibroblasts (non-reprogrammed cells, left panel) to 3-dimensional colonies evident at day 
13 after transgene induction (right panel). At day seven, cells showed first signs of 
reprogramming with the appearance of spheroid cell clusters with blurred cell borders (day 
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Figure 5  Schematic overview of the reprogramming set-up using lentiviral transduction 
nine) followed by formation of a colony with a clear and shiny border (day 11). 3-dimensional 
growth of reprogramming cells resulted in darker spots of dense cell clusters (day 13). At that 
stage, colonies were picked, resuspended in trypsin and single cells were replated on a layer 
of feeder cells (postmitotic MEFs). Doxycycline was withdrawn whenever colonies did not 
differentiate after picking and replating (between day 18-25 after transgene induction). After 
replating colonies for some passages, stable MEF-derived iPSCs (MEF-iPSCs) could be 
cultured on feeder cells in basic mESC medium in the absence of doxycycline and passaged 
as single cells. These cells were subjected to multiple assays to verify pluripotency. 
First, cultivation of established MEF-iPSCs on feeder cells resulted in 3-dimensional growth 
of cells that displayed typical iPSC morphology of round shape, large nucleoli, and scant 
cytoplasm [113] (Figure 6b). 24 hours after splitting, colonies were small and already 
showed shimmering borders typical for iPSCs (Figure 6b, left panel). Within four days cells 
grew 3-dimensionally and gave rise to large, packed, round-shaped iPSC-colonies 
(Figure 6b, middle panel). In addition, these colonies demonstrated alkaline phosphatase 
(AP) activity, which is a widely established sign for early reprogramming, indicating 
successful iPSC generation (Figure 6b, right panel). Lower magnification displays that 
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each colony was AP-positive and higher magnifications demonstrated clear boundaries 
between AP-positive colonies and feeder cells, which were clearly negative for this de-
differentiation marker (Figure 6b, right panel, arrowheads). In order to prove concrete 
upregulation of known pluripotency-associated markers, cells were tested for expression of 
Oct4, Sox2 and Nanog. Endogenous Oct4, Sox2 and Nanog was prominently upregulated on 
RNA-level in reprogrammed cells whereas RNA of these genes was absent in parental cells 
(Figure 6c). After reprogramming MEFs, the expression of endogenous Sox2 and Oct4 
reached about 50 % of the expression level in murine embryonic stem cells (mESCs) and 
Nanog as one of the key players in the pluripotency circuit was upregulated almost 3-fold in 
MEF-iPSCs compared to mESCs. FACS analysis supported qPCR data by verifying protein 
expression of all three markers (Figure 6d). 63.0 % of all single living cells were positive for 
SOX2. 59.6 % expressed NANOG, 66.8 % OCT4 and 46.7 % of all single living cells were 
OCT4/NANOG double positive. Next, I evaluated SOX2 expression in OCT4/NANOG double 
negative and OCT4/NANOG double positive subpopulations. Almost 90 % of cells that were 
negative for OCT4 and NANOG, did not show SOX2 expression indicating that this 
population was negative for all three markers and most likely consisted of feeder cells that 
were present due to the culture conditions for iPSCs. In line with that, almost 90 % of 
OCT4/NANOG double positive cells showed expression of SOX2 indicating a clear 
separation between triple negative and triple positive cells. Technical controls for FACS 
analysis indicated reliability since the isotype control did not show strong positive signals for 
the three markers (Figure 6e). Of note, there was a subpopulation that was OCT4 positive 
but did not express NANOG (Figure 6d, second left panel). In order to determine whether 
this was due to alternating expression of NANOG within one iPSC-colony or caused by 
NANOG negative colonies, which retained in an intermediate state of reprogramming, 
immunocytochemical testing for NANOG protein was performed. It demonstrated expression 
and moreover nuclear localization of this transcription factor (Figure 7a). As expected, post-
mitotic feeder cells were negative for NANOG protein and showed nuclear DAPI staining only 
(indicated by white arrowheads, Figure 7a middle panel). NANOG protein was clearly 
expressed in all colonies and showed heterogeneous expression within individual colonies. 
Taken together, qPCR and FACS data confirmed the stable state of pluripotency in MEF-
iPSCs since analyses were conducted after cells were cultured without doxycycline, and thus 
without transgene expression, for at least five passages. 
In addition to gene expression, also the differentiation potential of MEF-iPSCs was evaluated 
as a hallmark of pluripotency. Therefore, MEF-iPSC were cultured in hanging drops with 
approximately 50 cells per drop (50 µl MEF medium) for four days before they were pooled 
into 10 cm-culture plates in ten milliliters MEF-medium. Withdrawal of leukemia inhibiting 
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Figure 6  Reprogramming murine embryonic fibroblasts 
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Figure 7  Nanog expression in MEF-iPSCs and in vitro differentiation 
factor (LIF) present in mESC medium and the addition of fetal calf serum (FCS) within MEF 
medium resulted in spontaneous differentiation of MEF-iPSCs. After cultivation in FCS-
containing MEF medium for 23 days, this in vitro differentiation led to the appearance of 
MEF-iPSC-derived cardiomyocytes generating beating heart tissue, which could be identified 
by spontaneous contractions of cells (Figure 7b). 
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In summary, I successfully reprogrammed MEFs into MEF-iPSCs by using lentiviral vectors 
encoding for the four transcription factors Oct4, Sox2, Klf4 and c-Myc. MEF-iPSCs featured 
mESC-like morphology, alkaline phosphatase activity, endogenous expression of Oct4, Sox2 
and Nanog, and they were differentiated into contracting cardiomyocytes indicating 
enhanced differentiation potential into non-fibroblast cells. 
4.2. Reprogramming murine melanoma cell lines towards 
pluripotency 
The process of reprogramming somatic cells towards a pluripotent stage is currently under 
thorough investigation and essential pathways have already been elucidated (see 
section 1.2.4). However, the reprogramming process can also be used to gain further 
insights into tumorigenesis and cancer progression (see section 1.2.5). Thus, a novel system 
to reveal further connections between pluripotency and cancerous features can be 
established by reprogramming cancer cells towards a pluripotent state (see section 1.2.6). In 
order to use this system for melanoma research, I aimed to reprogram two murine melanoma 
cell lines. 
After establishing a variety of in vitro assays for proving pluripotency of reprogrammed cells, 
these assays were used to confirm successful reprogramming of two melanoma cell lines 
derived from the HGF/CDK4-melanoma mouse model (HCmel12 and HCmel17 cells, kindly 
provided by Prof. Thomas Tüting). These mice overexpress the hepatocyte growth factor 
(HGF) and carry an oncogenic mutation in the cyclin-dependent kinase 4 (CDK4R24C). Due to 
these genetic modifications, these mice spontaneously develop a spectrum of primary 
melanomas with high penetrance during their first year of life [211,212]. HCmel17 and 
HCmel12 cell lines are derived from a spontaneous melanoma of these mice, and from a 
transplanted HGF/CDK melanoma, respectively. 
According to the set-up for reprogramming MEFs (Figure 5), HCmel12 and HCmel17 cells 
were seeded in their regular medium, transduced with a polycistronic lentiviral vector 
encoding for Oct4, Sox2, Klf4 and c-Myc under the control of a doxycycline-inducible 
promoter, together with a lentiviral vector encoding for a constitutively active M2. Upon 
doxycycline administration, both cell lines showed morphological changes during the first two 
weeks similar to those that were observed when MEFs were reprogrammed. Figure 8a 
displays representative microscopic images of HCmel17 cells during colony formation. 
Similar to MEFs, melanoma cells started losing their normal dendritic morphology at day 
seven after onset of reprogramming. Small round cells appeared, clustered to colonies (day 
nine), which finally showed blurred cellular boundaries (day 11). At day 13, large colonies 
consisting of densely packed cells were observed and after some passages of picking these 
colonies, cells were cultured on feeder cells in order to establish fully reprogrammed induced 
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pluripotent cancer cells (iPCCs). IPCC-lines were successfully established from both parental 
cell lines HCmel12 and HCmel17 (hereafter referred to as HCmel12-iPCCs and HCmel17-
iPCCs, respectively). IPCC-colonies showed AP activity comparable to MEF-iPSCs 
(Figure 8b). In addition, OCT4, SOX2 and NANOG protein was markedly increased as 
shown by FACS analysis (Figure 8c-d). The percentage of SOX2 positive cells was 
increased from 1.56 % to 52.5 % and from 12.3 % to 76.4 % after reprogramming HCmel12 
and HCmel17 cells, respectively (Figure 8c, right panel). Similar to MEF-iPSCs, HCmel-
iPCCs showed separated positive and negative subpopulations regarding SOX2-expression. 
HCmel-iPCCs also showed OCT4/NANOG double positive cells (28.7 % or 34.6 % in 
HCmel12-iPCCs and HCmel17-iPCCs, respectively, Figure 8c). Comparable to MEF-iPSCs, 
more than 90 % of OCT4/NANOG double positive iPCCs also expressed SOX2 in both 
iPCC-lines indicating presence of a subpopulation that is positive for all three markers. In 
addition, 89.7 % and 72.0 % of NANOG/OCT4 double negative HCmel12-iPCCs and 
HCmel17-iPCCs, respectively, were also negative for SOX2 consistent with data derived 
from MEF-iPSCs (Figure 8d). Thus, the negative population is most likely composed of 
remaining non-reprogrammed feeder cells due to the feeder-dependent culture method for 
iPCCs. In addition, immunocytochemical analysis of HCmel17-iPCC-colonies supported 
FACS data by showing nuclear staining of OCT4, SOX2 and NANOG (Figure 8e). The 
heterogeneity of expression was in line with results from FACS analysis, since distribution 
was not homogenous within one iPCC colony. 
After performing in vitro assays to validate the pluripotency of reprogrammed melanoma 
cells, the differentiation capacity of these cells was assessed in vivo. Upon subcutaneous 
injections of parental and reprogrammed cells into mice, the generated tumors were excised 
and subjected to histological analyses. Parental HCmel12 cells induced the generation of a 
rapidly growing pigmented melanoma, whereas the reprogrammed counterpart created a 
more solid, non-pigmented tumor (Figure 9a). Histological analysis using hematoxylin and 
eosin (H&E) staining of paraffin-embedded tumor slices revealed that the HCmel12-derived 
melanoma consisted of a non-structured, homogenous tumor mass. Strikingly, the HCmel12-
iPCCs-derived teratoma contained cells derived from different germ layers such as cartilage, 
epithelial cells and gland-like structures (Figure 9a). 
Parental cells of HCmel17 did not form tumors after injecting up to 1x106 cells, whereas the 
reprogrammed counterpart generated a teratoma similar to the one derived from HCmel12-
iPCCs after injecting two confluent wells of a 6-well plate (Suppl. Figure 2). 
The time needed for a tumor to reach a diameter of 1.5 cm varied extremely between 
HCmel12 with 19 days and HCmel12-iPCCs with more than 30 days (Figure 9b). Of note, 
the number of injected iPCCs was different than that of parental cells because pluripotent 
cells are generally injected as clumps without previous single cell suspension and thus, 
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Figure 8  Colony-formation and expression of pluripotency-associated markers in melanoma cells after 
reprogramming 
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Figure 9  Teratoma formation in vivo 
counting is unreasonable. However, an 80 % confluent well of a 6-well plate generally 
contains more than 1x106 iPCCs. Therefore, despite lower cell number (5x105 cells), parental 
HCmel12 cells generated the melanoma faster than HCmel12-iPCCs created the teratoma. 
This indicates that reprogramming induced a reduction in proliferation capacity as well as 
changes in the cellular differentiation status. Decreased proliferation was confirmed by 
analysis of Ki67 expression on paraffin embedded tumor slices of the HCmel12-derived 
melanoma and the HCmel12-iPCC-derived teratoma. This marker is widely used to show 
proliferation since it is only expressed during G1-, S-, G2- and M-phase of the cell cycle. The 
melanoma derived from HCmel12 cells showed homogenous expression of Ki67, whereas 
the teratoma displayed a Ki67-positive area surrounding the tumor with Ki67-negative parts 
in the center, separated by a sharp border (Figure 9c, right panel, black arrowheads). 
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Table 3 Gene set enrichment analysis of 
HCmel12- and HCmel17-iPCCs  
In vitro assays in combination with in vivo differentiation confirmed successful reprogramming 
of melanoma cells towards full pluripotency (Figure 8-9). Next, differences between global 
gene expression signatures of parental melanoma cells, melanoma cell-derived iPCCs and 
control MEF-iPSCs were examined using total RNA for a hybridization-based expression 
microarray (Figure 10a). Total RNA was used in technical triplicates and microarray data 
were subjected to analysis using Chipster software. Gene expression data were quantile 
normalized (Illumina quantile normalization) and filtered for differentially expressed genes 
(empirical Bayes test, p≤0.05). Visualization using heatmap presentation demonstrated 
strong similarities between both iPCC-lines and vast differences between parental melanoma 
cell lines and their reprogrammed counterparts. Strikingly, the similarity between iPCCs and 
MEF-iPSCs was higher than the similarity between melanoma cells and their pluripotent 
equivalent indicated by the hierarchical cluster that shows Pearson distance. However, gene 
expression patterns between MEF-iPSCs and tumor-derived iPCCs revealed substantial 
differences so that iPCCs clustered together but 
with some distance to normal MEF-derived 
iPSCs. Heatmap presentation shows that some 
genes downregulated in MEF-iPSCs were still 
expressed in iPCCs and vice versa (Figure 10a). 
The melanocyte-associated gene set 
“upregulation of MITF in melanoma” was among 
the top ten pathways of commonly 
downregulated pathway maps in reprogrammed 
melanoma cells compared to their parental cell 
lines (map #6, Suppl. Table 1) with typical 
differentiation markers like Sox10, Tyrp2, Tyrp1 
and Mlana being significantly downregulated 
(Figure 10b).  
All gene ontology processes that were up- or 
downregulated after full reprogramming of 
melanoma cells are summarized in Table 3. Of 
note, the enrichment of processes involved in 
basic system development and differentiation 
indicated the complete conversion of 
differentiated cells into a cell type with higher 
developmental potential. Figure 10c illustrates 
one of the networks enriched in differentially 
expressed genes when HCmel17 cells were 
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Figure 10  Whole-genome expression analysis of melanoma cell line- derived iPCCs  
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compared to HCmel17-iPCCs (see also Suppl. Table 2). Consistent with data from qPCR 
and FACS analyses, the hybridization-based microarray detected upregulation of Nanog and 
Oct4 mRNA indicated by red circles, even in the absence of transgene expression. 
Interestingly, also the canonical Wnt-signaling pathway showed upregulation of specific 
genes that are known to be involved in established pluripotency, including Wnt and Wnt3a 
[213]. In addition, the mesoderm-lineage specifier Gata6 was significantly downregulated, 
illustrated by the blue circle, which indicates successful repression of lineage specifiers in 
combination with enhanced pluripotency-associated gene expression (Figure 10c). 
In summary, two melanoma cell lines were successfully reprogrammed. Both reprogrammed 
melanoma cell lines showed criteria of full pluripotency in vitro as well as in vivo 
demonstrated by gene expression and teratoma formation. Of note, differences between 
MEF-iPSCs and HCmel-iPCCs regarding global gene expression were observed indicating 
that iPCCs are still distinguishable from normal iPSCs. However, iPCCs are distinguishable 
from their parental melanoma cells lines and showed strong similarities with MEF-iPSC. This 
indicates that forced expression of four transcription factors resulted in resetting the complete 
molecular signature of HCmel cells. In line, subcutaneously injected reprogrammed HCmel-
iPCCs showed decreased proliferation indicating that pushing melanoma cells towards a 
pluripotent state alters their gene expression patterns and affects their cellular phenotype. 
4.3. Partial reprogramming of HCmel17 cells 
Having observed decreased proliferation by reduced Ki67 expression after reprogramming 
melanoma cells towards full pluripotency, the question arose, whether cellular changes were 
exclusively evident in the pluripotent state of melanoma cells or already detectable at earlier 
stages during reprogramming. 
Therefore, I established a novel protocol that allows to study a pure population of cells 
transduced with both, M2 and the reprogramming factors (Figure 11). HCmel17 cells stably 
co-expressing the M2 coupled to the fluorophore mCherry were generated (cells are 
hereafter referred to as HCmel17-M2) and sorted for mCherry expression with purity higher 
than 85 % using FACS (Suppl. Figure 3). In order to enable selection of transgene-
expressing cells, we substituted c-Myc from the doxycycline-inducible Stemcca-vector with a 
blasticidin resistance cassette (Stemca-blasti, Figure 12a) since c-Myc was endogenously 
expressed in HCmel17-M2 cells (Suppl. Table 3). 
HCmel17-M2 cells were seeded in 6-well plates in their regular medium and transduced with 
the Stemcca-blasti vector. Following another transduction 24 hours later, cells recovered 
overnight before they were used for further experiments. After three days of transgene 
expression induced by doxycycline administration in mESC medium, blasticidin was added to 
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select Oct4, Sox2 and Klf4-expressing cells. This protocol was established for investigating 
cellular functions at defined steps during reprogramming (Figure 11). 
After ten, 12 and 18 days, cells were subjected to different analyses. All assays were 
performed in the absence of doxycycline in order to inhibit further reprogramming and 
maintain the particular de-differentiation status. As a control, HCmel17-M2 cells were 
transduced with the Stemcca-blasti vector but not induced with doxycycline so that cells did 
not express transgenes. These control cells were cultured in the absence of doxycycline 
throughout all experiments. 
By day ten after transgene induction cells showed morphological alterations, e.g. clustering 
of small cells into groups with barely visible cellular borders (Figure 12b, right panel). Bigger 
clusters and colony formation were evident at day 12 and 18. In addition, AP-activity as a 
general indicator of early reprogramming and de-differentiation was detectable already at day 
ten with increasing activity at day 12 and 18 after transgene expression (Figure 12c, right 
panel). This indicated successful reprogramming in the absence of c-Myc. Cells that were 
cultured in the absence of doxycycline kept their normal morphology (Figure 12b, left panel)  
  
Figure 11  Schematic overview of the set-up for dissecting the reprogramming process in 
HCmel17 cells 
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and remained AP-negative indicating that AP-activity was a result of transgene expression 
(Figure 12c, left panel).  
Consistent with the indication of general de-differentiation, expression of Mitf, the key 
differentiation factor of the melanocytic lineage, was downregulated during the process of 
reprogramming (Figure 12d). Mitf levels decreased by more than 50 % by day 12 compared 
to basal level expression of this transcription factor in non-reprogrammed control cells. 
Accordingly, expression of Sall4, which is a downstream target of Oct4, Nanog and Sox2 
[147] and thus, an indicator of reprogramming, was increased in reprogrammed cells 
compared to control cells. These results demonstrated not only de-differentiation but also 
directed reprogramming towards pluripotency (Figure 12d) [214]. Since Sall4 is not 
expressed in non-reprogrammed control cells, expression levels were normalized to MEF-
iPSCs explaining the low increase in expression level (0.2 %). However, when comparing 
non-reprogrammed cells to reprogrammed cells at day 12 or day 18, a clear elevation of 
Sall4 expression was observed. 
In order to analyze global changes in gene expression and to further validate the stability of 
this biological process, non-reprogrammed control cells and cells reprogrammed for ten, 12 
and 18 days were subjected to a hybridization-based gene expression microarray in 
independent biological triplicates. Completely reprogrammed HCmel17-iPCCs as well as 
MEF-iPSCs from previous experiments were included into the analysis. Figure 12e shows 
the heatmap of all significantly expressed genes (p≤0.005). Every row represents a gene 
(292 genes in total) and every column one sample. 
Biological replicates from each sample clustered closely together indicating a biologically 
stable process of de-differentiation during partial reprogramming. MEF-iPSCs and HCmel17-
iPCCs grouped together with some distance to partially reprogrammed cells. Non-
reprogrammed control cells (-Dox) represented the group with the largest distance compared 
to all non-parental cells. The shift from up- to downregulated and from down- to upregulated 
genes reflected the gradual change of global gene expression during reprogramming. 
Interestingly, the gene expression signature in cells partially reprogrammed for ten to 
18 days revealed a group with significant difference in gene expression when compared to 
their parental cell line or to their fully reprogrammed counterparts (Figure 12e). Gene set 
enrichment analysis of genes downregulated in partially reprogrammed cells (12 days) 
compared to non-reprogrammed cells included processes related to positive regulation of cell 
differentiation indicating the switch from a differentiated melanoma cell towards a more de-
differentiated type of cell (Suppl. Table 4). 
In summary, these results indicate that HCmel17 cells were successfully reprogrammed to 
different stages of de-differentiation. Notably, this complex biological process could be 
reproduced with high accuracy. 
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Figure 12  Partial reprogramming of HCmel17 cells 
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Table 4 Gene set enrichment analysis of pathways in 
partially reprogrammed HCmel17 cells 
Next, I wanted to identify cellular processes that were strongly affected by partial 
reprogramming. Gene set enrichment analysis of both, up- and downregulated genes 
(p≤0.05) at day 12 after induction of transgene expression compared to non-reprogrammed 
HCmel17 cells revealed that the majority of processes affected by partial reprogramming 
were involved in cell adhesion and cytoskeleton remodeling (Table 4). Since cell adhesion 
and cytoskeleton remodeling are of huge importance in cancer cells’ acquisition of invasive 
potential, I aimed to further investigate this functionally in partially reprogrammed melanoma 
cells. Therefore, the invasion through an artificial basal embrane was examined in three 
independent experiments in technical 
triplicates (Figure 13a). Cells were 
seeded in serum-free medium on top of 
an artificial basal membrane and 
invasion through this layer towards 
serum-containing medium was 
measured. Strikingly, the invasive 
capacity of HCmel17 cells increased 
significantly in a transient manner 
showing a threefold increase after 
12 days of reprogramming (p≤0.05) with 
a subsequent significant decrease at 
day 18 after induction of transgene 
expression (p≤0.05). 
Other cell lines were subjected to partial 
reprogramming by transducing them with 
M2-mCherry and Stemcca-blasti. MEFs, 
a hepatocellular carcinoma cell line 
(Hepa1.6, kindly provided by Prof. 
Klingmüller) and an additional melanoma 
cell line (Ret2, kindly provided by Prof. 
Umansky) were used. Figure 13b 
illustrates the percentage of invasion 
capacity through an artificial basal 
membrane comparing cells 
reprogrammed for 12 days to non-
reprogrammed control cells. Strikingly, 
only cell lines that generated AP-positive  
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Figure 13  Partial reprogramming alters invasion and proliferation capacity of HCmel17 cells  
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colonies by day 12 upon transgene expression showed increased invasive potential. Hep1.6 
displayed a two-fold increase in invasion compared to control cells and MEFs increased their 
invasive potential almost three-fold. Both cell lines showed AP-activity. In contrast, Ret2 cells 
displayed neither morphological changes nor AP-activity after transgene expression for 
12 days although cells were viable despite blasticidin selection indicating intact transgene 
expression. Strikingly, no changes regarding their invasive potential was observed 
(Figure 13b). These data demonstrated that increased invasive potential of partially 
reprogrammed murine cell lines depended on successful reprogramming but transgene 
expression alone was not sufficient to induce this invasive phenotype. 
In order to confirm the higher invasive potential of partially reprogrammed HCmel17 cells in 
vivo, a tail vein assay in syngeneic C57BL/6 mice was performed. 5x105 HCmel17 cells, 
reprogrammed for 12 days or non-reprogrammed, were injected intravenously into C57BL/6 
mice and mice were sacrificed six weeks after injection. To analyze extravasation potential of 
cells, lungs of all animals were excised, weighted and fixed for histological analysis. 
Metastases could be identified in lungs derived from mice injected with partially 
reprogrammed cells (Figure 13c, right panels, arrowheads), whereas lungs from control 
animals showed normal lung histology without infiltrating tumor cells (Figure 13c, left panel). 
In line with that, the weight of lungs derived from mice injected with partially reprogrammed 
cells was significantly higher (253.8 mg ± 43.19 mg, n=5, p≤0.05) when compared to lung 
weight of animals injected with control cells (175.0 mg ± 5.766 mg, n=3, Figure 13d). 
After showing increased invasive potential of partially reprogrammed cells in vitro and in vivo, 
proliferation changes during the process of reprogramming were analyzed. In order to 
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investigate if and how proliferation was influenced by partial reprogramming, cells were 
harvested at day 12 or 18 after onset of reprogramming and seeded in 96-well plates to be 
subjected to proliferation analysis. Partial reprogramming for 12 or 18 days resulted in 
significantly decreased proliferation compared to non-reprogrammed counterparts 
(Figure 13e). Already at day 12, proliferation was decreased by more than 60 % with a slight 
increase at day 18. In order to test this alteration in vivo, 1x106 of partially reprogrammed 
cells (day 12) or 5x105 non-reprogrammed control cells were injected subcutaneously into 
mice. After excision of tumors with a size of 1.5 cm (-Dox: 76 days; +Dox: 70 days), they 
were subjected to immunohistochemical analysis of Ki67 expression, a widely established 
proliferation marker. The tumor derived from partially reprogrammed cells demonstrated 
fewer Ki67-positive cells compared to the tumor derived from control cells indicating 
decreased proliferation (Figure 13f), which is consistent with data derived from in vitro 
analysis. 
In summary, partially reprogrammed HCmel17 cells at day 12 after transgene induction 
demonstrated increased invasion capacity with decreased proliferation in vitro and in vivo. In 
vitro findings further showed that the elevated invasion capacity was a transiently occurring 
phenomenon that was reversed at day 18. 
 
Taken together, the analysis of global gene expression signatures revealed that cytoskeleton 
remodeling was among the top ten pathway maps enriched in differentially expressed genes 
on day 12 of reprogramming. In addition, these cells demonstrated significantly increased 
invasive potential in vitro and in vivo.  
Interestingly, it was shown that breast cancer cells use the cytoskeleton remodeling process 
as the major route in order to gain invasive potential, in contrast to cells from other cancer 
types that favor proteolytic invasion [215]. In order to analyze the expression of genes, which 
are associated with highly invasive breast cancer cells, these gene sets were extracted from 
the whole genome expression analysis of partially reprogrammed cells compared to non-
reprogrammed control cells ([216], Figure 13g). Genes that are upregulated in invasive 
breast cancer cells and differentially regulated after partial reprogramming could be 
separated into two groups: about half of them were also upregulated at day 12 after 
reprogramming, whereas the other half showed the opposite expression pattern with 
decreased expression at day 10 and 12 and increased expression at day 18. The first group 
of genes showing increased expression in highly invasive breast cancer cells as well as in 
partially reprogrammed cells (day 12) included genes that are known to play important roles 
in cytoskeleton remodeling during development and in cancer progression, i.e. Shroom3 
[217], Atp1a1 [218], and Atp6v1c1 [219]. Also a major constituent of microtubules, Tubb2b, 
was upregulated indicating that cytoskeleton remodeling is a key event not only in invasive 
breast cancer but also in partially reprogrammed HCmel17 cells. In contrast, genes that were 
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shown to be upregulated in invasive breast cancer cells but downregulated at day ten and 12 
of partial reprogramming included well known factors that drive EMT in somatic and 
tumorigenic cells, i.e. Glipr-2 [220] and fibronectin (fn1, [221]). 
Strikingly, between day 12 and 18 the upregulation of invasion-related genes demonstrated a 
strong switch, whereas day ten and 12 share similar expression of invasion-related genes 
(Figure 13g). This expression profile of invasion-related genes, which showed a clear switch 
in expression between day 12 and 18, was in agreement with observed functional changes. 
4.4. Identification of potential invasion-related genes 
Since HCmel17 melanoma cells reprogrammed for 12 days showed a significant increase in 
their invasive potential in vitro and in vivo, expression of invasion-related genes became 
focus of investigation. Figure 14a displays the fold change expression of neural crest-related 
genes, which have been previously shown to be linked to invasion [75], during the process of 
reprogramming including fully reprogrammed HCmel17-iPCCs. Strikingly, partial 
reprogramming for 12 days and accelerated invasion potential did not correlate with 
expression of neural crest-related markers. Independent of the involvement of these genes 
within the neural crest signaling cascade, i.e. induction, specification, EMT/invasion, genes 
were mainly downregulated while cells were converted to a pluripotent state. Nes was the 
only gene that was expressed slightly higher at day ten and 12 compared to non-
reprogrammed cells or cells reprogrammed for 18 days, respectively (Figure 14a). In 
addition, markers, which were shown to be up- or downregulated after the phenotype switch 
from proliferative to highly invasive melanoma cells in previous studies [77,100,222], did not 
correlate with the phenotypic change of melanoma cells that were reprogrammed for 12 days 
(Figure 14b). Downregulation of Ror1, Zeb2, Snai2 and Phf19 was demonstrated to 
correlate with increased invasion, as was the upregulation of Ror2 and Zeb1 [77,100,222]. In 
contrast, in melanoma cells partially reprogrammed for 12 days, which show increased 
invasion in combination with decreased proliferation, these genes were not significantly 
altered between day 12 and 18 (Figure 14b). Of note, Zeb1 and Snai2 were strongly 
downregulated in completely reprogrammed HCmel17-iPCCs. 
In addition, Mmps, which were previously shown to be to related to melanoma cell invasion 
[85,87–90], were not upregulated at day 12 after reprogramming. In contrast, expression of 
Mmp3, Mmp2 and Mmp14 was strongly decreased during the process of reprogramming with 
maximum decrease in completely reprogrammed HCmel17-iPCCs compared to non-
reprogrammed control cells (Figure 14c).  
Next, I aimed to identify novel genes, which expression correlated with this transient invasive 
phenotype. Therefore, Chipster software was used to filter genes, which were significantly 
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Figure 14  Identification of SNAI3 as a novel invasion-related marker in melanoma 
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upregulated at day 12 compared to their parental cells (p≤0.05; FC≥3.00) followed by 
decreased expression at day 18 (p≤0.05, FC≤2.00; Figure 14d). Next to Carcinoembryonic 
antigen-related cell adhesion molecule 1 (Ceacam1), Follistatin (Fst) was among the top five 
genes. Since a closely related protein of Fst (Fstl-1) was connected to invasive potential and 
Snai1-induced EMT in cancer cells [223], I aimed to elucidate the role of SNAI-family 
members in this invasive phenomenon. First, I validated Fst expression by qPCR showing an 
increase at day 12 after induction of partial reprogramming and subsequent downregulation 
at day 18 being consistent with expression data derived from the microarray (Figure 14e). In 
addition, expression of Snai1 (Snail), Snai2 (Slug) and Snai3 was analyzed. Neither of the 
first two members, which are known regulators of EMT processes in cancer cells, showed 
increased expression, which would explain the invasive potential of HCmel17 cells 
reprogrammed for 12 days. Strikingly, the third member of this transcription factor-family, 
Snai3, was highly upregulated in HCmel17 cells reprogrammed for 12 days in combination 
with subsequent downregulation at day 18 (Figure 14e). 
In addition, other well-known genes, which are deregulated when melanoma cells acquire an 
EMT-induced invasive phenotype including Sparc and Cdh2 and Cdh1, were analyzed by 
qPCR (Figure 14f). Neither Sparc nor Cdh2 was upregulated at day 12. In addition, Cdh1 
that is frequently downregulated upon EMT induction in carcinomas to promote invasion was 
upregulated at day 12. 
In order to find out whether Snai3 is also expressed in vivo its expression was analyzed in 
tumors derived from partially reprogrammed cells (day 12) that had been subcutaneously 
injected into mice. Representative microscopic images are displayed in Figure 14g. Partially 
reprogrammed cells that exhibited highly upregulated Snai3 expression in vitro showed areas 
of high SNAI3 protein expression as well as SNAI3 negative areas in vivo indicating a 
heterogeneous expression of this marker in tumors. Moreover, the expression of SNAI3 in 
lung metastases from the tail vein assay was analyzed. Interestingly, not all lung infiltrating 
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tumor cells showed positive signals for SNAI3 in established metastases (Figure 14h, 
arrowheads) but rare tumor cells showed expression of SNAI3 (Figure 14h, white asterisk). 
In summary, the model of partial reprogramming and subsequent in vitro as well as in vivo 
analyses revealed a phenotype switch of melanoma cells with increased invasion and 
decreased proliferation at day 12 after transgene induction. This phenotype switch was 
independent of neural crest-related gene expression. In addition, expression of genes that 
have been suggested to label the phenotype switch in melanoma cells did not correlate with 
observed functional alterations. This indicates that my system of partially reprogrammed 
tumor cells can be used to identify novel pathways that might drive the phenotype switch in 
melanoma cells. Importantly, this in vitro system can be used to find genes that are 
expressed according to the observed phenotype and thus, allows to identify novel 
biomarkers for the phenotype switch. Here, I demonstrate that Snai3 is regulated in 
correlation with the functional changes after the phenotype switch indicating a role for this 
transcription factor in acquisition of invasive potential in melanoma cells.  
 
4.5. SNAI3 as a putative marker for invasive potential in 
melanoma 
4.5.1. SNAI3 expression and its relevance in the clinic 
The SNAI transcription factor family is heavily involved in the acquisition of invasive 
properties during normal development but also in tumor progression. Its novel member, 
SNAI3 has just recently been identified in humans and thus, its role in cancer is completely 
unknown. Hints from microarray analyses indicated a role of SNAI3 in the phenotype switch 
of partially reprogrammed cells, why I further analyzed SNAI3 expression in vivo in order to 
explore whether it correlates with invasive potential of melanoma cells. Therefore, paraffin 
embedded primary tissues from melanoma patients were stained for SNAI3. Figure 15a 
shows representative images of SNAI3 expression in a melanocytic nevus and a primary 
melanoma in different magnifications. SNAI3 was present in normal human keratinocytes in 
the epidermis consistent with data published in the human protein atlas (Figure 15a, left 
panel, arrowheads, [224]). Melanocytic nevus cells were hardly stained for SNAI3, whereas 
the primary tumor showed diverse SNAI3 expression with strongest signals in deeper regions 
of the tumor (Figure 15a, right panel). These results indicate a role of SNAI3 in invasiveness 
of melanoma cells since its expression was mainly detected on invasive sides of tumors (in 
deeper regions of primary melanoma). To elucidate the expression of SNAI3 in a bigger 
cohort of patients, its expression was analyzed using a tissue microarray (TMA) containing 
human benign intradermal melanocytic nevi (n=37) and biopsies collected from primary 
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Figure 15  SNAI3 expression correlates with tumor thickness  
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melanomas (n=26). SNAI3 was detected in parts of nevi (Figure 15b, left panel) and primary 
melanomas of low risk (≤1mm tumor thickness, Figure 15b, middle panel) or high risk 
(≥1mm tumor thickness, Figure 15b, right panel), respectively. In addition to another 
independent researcher, I measured expression intensity and quantity in a blind setting using 
a defined immunohistochemical (IHC) score (Figure 4). Strikingly, SNAI3 expression and 
depth of primary melanomas (Breslow score) correlated and a significant increase in the IHC 
score for SNAI3 was observed in all pooled primary melanomas compared to nevi 
(Figure 15c). In order to discover at what exact step of melanomagenesis SNAI3 expression 
increases, comparative analysis was performed between low-risk and high-risk primary 
melanomas (Figure 15d). The significant difference between nevi and high-risk melanoma 
regarding the IHC score was further increased, which indicates that high-risk melanoma are 
tumors, which retain the highest IHC score for SNAI3 in the pool of primary melanomas. 
Remarkably, the IHC score is also significantly increased comparing low-risk with high-risk 
melanomas (Figure 15d). 
4.5.2. SNAI3-overexpression in human melanoma cells lines 
To further elucidate SNAI3’s particular role in melanomagenesis, gain of function studies 
were performed. Therefore, four human melanoma cell lines were transduced with an 
expression vector encoding for human SNAI3, or with the pLX304 control vector (pLX), 
respectively. Both vectors carried a blasticidin resistance cassette and cells were used for 
overexpression confirmation and functional assays after selecting with blasticidin for at least 
ten days at defined concentrations (Table 1). Next to melanoma cell lines, immortalized 
human fibroblasts were examined in parallel as an additional, non-tumorigenic control. 
Overexpression of SNAI3 was validated in authenticated human melanoma cells lines A375, 
Mewo, SKmel28, SKmel30 and human immortalized fibroblasts on RNA level using qPCR 
(Figure 16a). Gapdh was used as the endogenous control and data were normalized to 
immortalized human keratinocytes as SNAI3 is known to be expressed in these cells [224]. 
The pLX-transduced control cells showed expression levels of SNAI3 that were just above 
the detection threshold. Strikingly, transduction with the overexpression vector resulted in a 
3,000-30,000-fold increase of SNAI3 mRNA in all cell lines tested compared to keratinocytes. 
Immunoblot analysis validated overexpression in three out of four cell lines with α-ACTININ 
serving as the loading control (Figure 16b). SKmel28 did not show any SNAI3 protein 
expression in neither pLX-transduced or SNAI3-OE vector-transduced cells. Immortalized 
human fibroblasts did not grow after transduction with the SNAI3 construct and therefore 
could not be used for protein extraction or other analyses. 
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Figure 16  SNAI3 overexpression in human melanoma cell lines 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
- Results - 
- 78 - 
 
 
 
 
 
 
 
 
 
 
 
 
Quantification of immunoblots using ImageJ revealed a four to 100-fold increase of SNAI3 
protein in melanoma cell lines with Mewo cells showing the strongest overexpression, and 
A375 and SKmel30 a slight expression when transduced with SNAI3-OE vector 
(Figure 16b). When transduced with the control vector pLX, only A375 cells showed little 
expression of SNAI3 on protein level supporting qPCR data that demonstrated mRNA 
quantity, which was just above detection level for all cells lines. Of note, little protein 
presence in pLX control cells lead to strong variances regarding the quantification of fold-
changes. In order to confirm protein expression, immunocytochemical analysis was 
performed. Cells were seeded in 8-well chamber-slides and incubated under normal growth 
conditions for 12 hours. After staining using an anti-SNAI3 antibody overnight they were 
incubated with an Atto488-labeled secondary antibody (green). Representative pictures are 
shown in Figure 16c. In line with results derived from immunoblot analysis, A375 cells 
demonstrated slight SNAI3 expression when transduced with the control vector pLX but 
showed stronger staining of SNAI3 when transduced with the SNAI3-OE construct. 
Expression data derived from immunoblot analysis could also be verified for SKmel28 since 
SNAI3-staining showed barely any SNAI3 expression with no difference between cells 
transduced with the control vector or the SNAI3-OE construct. Fluorescence images of Mewo 
cells revealed a strong expression of SNAI3 when transduced with the SNAI3-OE construct 
compared to control cells and SKmel30 also demonstrated stronger staining for SNAI3 when 
transduced with the SNAI3-OE construct. In summary, immunocytochemical analysis 
confirmed data derived from immunoblot analysis and showed overexpression of SNAI3 on 
protein level in three out of four cell lines. Due to lack of SNAI3 expression when transduced 
with the SNAI3-OE construct, SKmel28 cells were excluded from further analyses. 
After confirmation of SNAI3 overexpression in the three cell lines A375, Mewo and SKmel30, 
these cells were used to investigate changes in cellular functions. Morphological alterations 
upon SNAI3 overexpression were not observed in any of the cell lines (Figure 16d). Of note, 
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fibroblasts showed morphological changes towards a senescent-like phenotype with swollen 
cytoplasm and a visible nucleus. They did not proliferate after SNAI3 transduction and were 
not further analyzed. 
Next, proliferation, migration and invasion capacity of cells overexpressing SNAI3 were 
investigated in order to identify its functional impact on melanoma cells. Proliferation capacity 
was assessed and is displayed as percentage of proliferation in pLX-transduced control cells.  
All melanoma cell lines showed significantly reduced proliferation (Figure 16e) but they could 
be continuously cultured in regular medium. 
Migration as well as invasion potential was assessed using a combined transwell-chamber 
system. Therefore, cells were seeded into the top chamber of the transwell-system in serum- 
deprived medium and migration through established pores (migration) or through additional 
coating containing basal membrane equivalent (invasion) towards serum-containing medium 
in the bottom chamber was measured. Exclusively A375 showed a tendency to increased 
migration as well as increased invasion potential when SNAI3 was overexpressed but Mewo 
and SKmel30 cell lines did not exhibit altered migratory (Figure 16f) or invasive capacities 
(Figure 16g). However, this increase in migration and invasion in A375 cells was not 
significant. 
In order to test for de-differentiation and to detect potential differences in gene expression of 
invasion-related genes, qPCR analysis was performed for de-differentiation-associated, 
EMT-related, or invasion-related genes (Figure 17). All expression data were normalized to 
Gapdh as the endogenous control. Normal human melanocytes (NHM) served as the 
reference sample for differentiation-related markers (DCT, MITF, TYRO) in order to cross-
compare expression between cell lines. The melanocyte-specific genes DCT, MITF and 
TYRO were absent or barely expressed in A375 and Mewo cells even without 
overexpressing SNAI3 so that no alteration of expression could be detected (Figure 17a). 
SNAI3-overexpression in SKmel30 cells resulted in reduced expression of all three 
differentiation-associated factors. Of note, with about four percent of expression levels 
compared to NHM, TYRO and DCT could only be detected at very low levels in pLX-
transduced control cells so that the reduction caused by SNAI3-overexpression is not 
necessarily biologically relevant. In contrast, MITF was reduced compared to NHM from 
about 25 % to 10 % and this might indicate a de-differentiation of cells upon SNAI3 
overexpression.  
Except for the differentiation markers, all expression data were normalized to the pLX-
transduced control cells (Figure 17b). Interestingly, the other family members of the SNAI 
family (SNAI1 and SNAI2) were not affected regarding their expression levels in A375 and 
Mewo cells, whereas in SKmel30 cells, SNAI1 was strongly reduced to about 20 % and 
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Figure 17  Expression of invasion-related genes in SNAI3-overexpressing melanoma cells 
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SNAI2 showed a moderate downregulation to 60 % compared to pLX-transduced control 
cells. In addition, ZEB2 was heterogeneously expressed in these three melanoma cells lines 
upon SNAI3-overexpression whereas ZEB1 remained at the same expression levels after 
exogenous SNAI3 expression. Another known EMT- and invasion-related marker, TWIST1, 
did not show enhanced expression upon SNAI3-overexpression. Analysis of other de-
differentiation-related markers (CD271, CDH2) revealed that there was no clear direction the 
cells were driven to regarding their phenotypic status in line with results from functional 
assays. CDH2 was decreased in A375 and SKmel30 but did not show deregulation in Mewo 
cells upon SNAI3-overexpression. Expression of CD271 was downregulated in A375 and 
SKmel30 but did not show any de-regulation in Mewo after SNAI3-overexpression 
(Figure 17b). These data are in line with the absence of functional differences when SNAI3 
was overexpressed in human melanoma cell lines. 
Taking all data into account, this study shows that overexpression of SNAI3 in human 
melanoma cell lines is not sufficient to induce the enhanced invasion capacity observed in 
murine melanoma cells upon partial reprogramming. However, SNAI3 expression possesses 
clinical relevance due to its correlation with tumor thickness and a significant increase in 
expression comparing low-risk to high-risk primary melanomas. 
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5. Discussion 
Reprogramming of cancer cells towards pluripotency has been studied in recent years 
[184,185,187,225,226]. However, the stepwise conversion of malignant cells with possible 
changes of cellular functions during the process of reprogramming has not been 
investigated. Here, I demonstrate that partial reprogramming of murine melanoma cells is a 
time-dependent and reproducible in vitro model that mimics the phenotype switch from highly 
proliferative and less invasive into less proliferative and highly invasive melanoma cells. In 
addition, this in vitro model led to the identification of SNAI3 as a novel invasion-related 
marker with potential prognostic value for melanoma patients. 
5.1. Murine melanoma cells can be reprogrammed towards full 
pluripotency 
A range of in vitro assays confirmed pluripotency in HCmel12- and HCmel17-iPCCs. Cellular 
morphology, alkaline phosphatase activity and expression of pluripotency-associated 
markers including Oct4, Sox2 and Nanog, verified the pluripotent state of melanoma cell-
derived iPCCs (Figure 8). In addition, whole genome expression analysis revealed a gene 
expression signature comparable to that of MEF-iPS control cells and a strong separation 
from parental cells (Figure 10). This indicates that the conversion of HCmel cells into a 
pluripotent state results in a switch of transcriptome identity as previously shown for 
reprogrammed cancer cells [184]. In addition, in vivo differentiation demonstrated the 
capacity of HCmel12- and HCmel17-iPCCs to differentiate into cells derived from different 
germ layers by generation of teratomas upon subcutaneous injections (Figure 9a, Suppl. 
Figure 2). This is in agreement with other studies showing that reprogramming cancer cells 
to a pluripotent state enables them to terminally differentiate into different cell types [185]. 
Moreover, all pluripotency validating assays were performed after established iPCCs have 
been cultured for at least five passages in the absence of doxycycline. This approves the 
stability of their pluripotent state independent from exogenous transgene expression. Taken 
together, these data are in agreement with previously published studies showing the 
conversion of murine melanoma cells into a pluripotent state with an increase of Sox2 and 
Oct4 expression and successful teratoma formation [141]. Thus, I successfully 
reprogrammed two melanoma cell lines towards pluripotency with subsequent differentiation 
into cells from different germ layers. The fact that parental HCmel17 cells did not induce 
melanoma generation in vivo upon subcutaneous injections can be explained by variances in 
the procedure of injection. However, HCmel17-M2 cells transduced with Stemcca-blasti in 
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the absence of doxycycline generated tumors upon subcutaneous injections confirming the 
tumor initiating capacity of these cells (Figure 13f, left panel). 
The observed reduction of Ki67 expression in HCmel-iPCC-derived teratomas indicates 
diminished proliferation. Thus, reprogramming towards pluripotency has effects on cellular 
functions that are essential for tumor formation, i.e. proliferation. This further supports other 
studies showing that reprogrammed cancer cells, which are subsequently differentiated into 
different lineages, show reduced proliferation with abrogation of tumorigenicity in vivo 
[186,187]. In agreement with this, HCmel-iPCCs generated differentiated cells from different 
lineages in vivo supporting the hypothesis that upon reprogramming, cancer cells lose their 
original morphology and can be converted into terminally differentiated cell types as 
demonstrated by other reprogrammed cancer cells that were successfully differentiated in 
vitro (Figure 9a, [186]). Data from the current study further indicate that the proliferation 
capacity of cancer cells can be altered experimentally by converting them into a pluripotent 
state. 
Since reprogramming is a complex process involving successive picking and replating of 
colonies, contamination with other cells is possible. In order to confirm identity of HCmel cells 
before and after reprogramming, cell lines were authenticated using microsatellite markers 
for genotyping and showed 100 % consensus, which proves genetic identity of parental and 
reprogrammed cells (section 3.1.5). Although methylation status of particular loci as another 
method to prove altered gene expression regulation [141,185,186] has not been investigated 
in this study, global gene expression signatures confirm the conversion of HCmel melanoma 
cells towards a pluripotent state (Figure 10). 
5.2. Partial reprogramming of melanoma cells is a stable process 
with time-dependent changes in gene expression 
In order to dissect the reprogramming process of melanoma cells, this process was 
evaluated regarding its stability and biological reproducibility. The examination of the timeline 
for reprogramming HCmel17 cells revealed colony-formation within seven to 13 days 
(Figure 12b). This is consistent with the reprogramming time line of HCmel17 cells using the 
Stemcca vector (Figure 8), where cells showed similar morphological changes within the 
same time frame. This indicates that the absence of exogenous c-Myc in HCmel17-M2 cells 
transduced with Stemcca-blasti did not result in delayed reprogramming. The endogenous 
expression level of c-Myc in HCmel17-M2 cells transduced with Stemcca-blasti without 
doxycycline administration was identical to that of established HCmel17-iPCCs (Suppl. 
Table 3) and therefore sufficient to reprogram HCmel17-M2 cells without exogenous 
expression of this factor. This is in agreement with other studies showing that endogenous 
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expression of particular reprogramming factors enables reprogramming with less than four 
factors [141,227,228]. 
Strikingly, reprogramming of melanoma cells represents a stable and reproducible process 
that comprises gradual changes of global gene expression correlating to the time of 
transgene expression (Figure 12e), which is in line with detailed analyses of the 
reprogramming process in MEFs that revealed reproducible and defined steps throughout 
reprogramming [151]. Although regulation of particular genes, such as downregulation of 
Thy-1, is known as a reliable indicator during reprogramming of MEFs, the exact same 
markers cannot be used to measure reprogramming in melanoma cells due to the lineage-
dependent absence of these genes in melanoma cells compared to MEFs [150]. However, 
Mitf as a driver of melanocytic differentiation was downregulated by day 12 of reprogramming 
indicating successful de-differentiation (Figure 12d). Whether this key player in melanocytic 
development is downregulated as early as three days after transgene expression, 
comparable to Thy-1 in fibroblasts, remains subject of investigation [150]. 
Importantly, melanoma cells show a gradual change in global gene expression between day 
ten, day 12 and day 18 and all partially reprogrammed cells cluster closer to their pluripotent 
equivalent than to their parental cell lines indicating that the transcriptional profile of 
melanoma cells is already lost after ten days of reprogramming (Figure 12e). This is in line 
with descriptions of the reprogramming process of normal fibroblasts [150]. In addition, 
HCmel17-derived iPCCs cluster closer to MEF-iPSCs than to the partially reprogrammed 
HCmel17 cells demonstrating that essential steps take place between day 18 and full 
attainment of the pluripotent state. This is a difference compared to MEFs reprogrammed 
with Oct4, Sox2, Klf4, and c-Myc, since they show stable gene expression changes at day 
nine and onwards, and enter stable pluripotency already at day 12  [151]. Of note, early 
morphological changes were detected at similar time points during reprogramming of MEFs 
and HCmel17 cells (Figure 6a, 8a). Therefore, it is likely that early events are similarly 
regulated but acquisition of full pluripotency is delayed in melanoma cells-derived iPCCs. 
This delay in reprogramming can be explained by the fact that HCmel17 cells harbor 
mutations that might affect reprogramming efficiency. In depth analysis is required to identify 
underlying mechanisms. 
Non-reprogrammed control cells have been cultured in the same medium like reprogramming 
cells and did not show a gene expression signature comparable to partially reprogrammed 
cells (Figure 12e), excluding possible influences of growth factors within the medium to 
cause changes in gene expression. Also, doxycycline treatment as well as blasticidin 
selection did not cause reprogramming-associated changes since cells reprogrammed for 
different periods (ten, 12, 18 days) showed significantly deregulated gene expression when 
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compared to each other, demonstrating that gene expression alterations are truly caused by 
transgene expression and subsequent reprogramming of the cells. 
The change in gene expression during reprogramming indicates a gradual conversion of 
melanoma cells into iPCCs via expression of transgenes. The analysis of pluripotency-
associated marker expression further confirms true reprogramming (AP, Sall4; Figure 12c-
d). The fact that murine melanoma cells are reprogrammed in a reproducible way with a 
time-dependent change in gene expression profiles reveals that this in vitro model can be 
used as a tool to further investigate melanoma cells on their route to acquire pluripotency. 
This can help to understand molecular events and find novel markers that are associated 
with disease progression, since particularly in melanoma, de-differentiation is associated with 
metastatic spread, poor prognosis and drug resistance [66,229].  
Due to their capability to reprogram within days, mouse cells were chosen for this technical 
approach. However, it will be interesting to assess whether human melanoma cells show 
comparable expression changes in a similarly stable shift towards pluripotency. Comparable 
analysis might reveal underlying mechanisms that are conserved between species. It is also 
of interest whether reprogramming-induced gene expression changes can also be observed 
in a two-wave pattern in melanoma cells as it is reported for MEFs [151]. Therefore, deeper 
analyses of epigenetic modifications including DNA-methylation, changes in chromatin 
structures and histone modifications will be needed to fully dissect this process in melanoma 
cells [151,153]. Nevertheless, I illustrate for the first time the stable and time-dependent 
conversion of murine melanoma cells towards a pluripotent state and provide a novel 
platform for investigating changes in melanoma cells associated with directed de-
differentiation. 
5.3. Partial reprogramming induces a transient phenotype switch 
in HCmel17 cells 
Partial reprogramming of melanoma cells revealed a transiently occurring phenotype switch 
that was accompanied by elevated invasive potential in combination with decreased 
proliferation. Gene set enrichment analysis of up- and downregulated genes at day 12 after 
induction of transgene expression revealed that the majority of pathways affected by partial 
reprogramming were involved in cell adhesion and cytoskeleton remodeling (Table 4). This is 
in agreement with morphological alterations and 3-dimensional growth of melanoma cells 
during the reprogramming process (Figure 12b) that has also been described for other cells 
when reprogrammed [150]. Cell adhesion and cytoskeleton remodeling-related processes 
are also strongly involved in mediating cellular motility and tumor cell invasion [86,87,91]. In 
line with this, functional analyses in the current study disclosed significantly enhanced 
invasion capability through basal membrane equivalent in vitro and significantly increased 
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lung colonization in vivo at day 12 of reprogramming (Figure 13a, d). This increase in 
invasion combined with decreased proliferation at day 12 after transgene induction mimics 
the phenotype switch in melanoma cells from highly proliferative to highly invasive cells 
[97,98,102]. Decreased proliferation of partially reprogrammed cells in vitro was determined 
by alamarBlue - a vital dye, which is metabolically reduced by cellular enzymes to a 
fluorescent product that can be measured using standard fluorescence plate readers. 
Although this assay is widely established as an adequate measurement of cellular 
proliferation [230–232], the appearance of metabolic changes in partially reprogrammed 
cells, which may affect the results of alamarBlue reduction, cannot be ruled out. However, 
further in vivo analysis supported in vitro data by demonstrating reduced Ki67 expression in 
tumors derived from partially reprogrammed cells, confirming diminished proliferation 
(Figure 13e, f).  
So far, only the cultivation of melanoma cells in neural crest medium has been shown to 
induce phenotype switching in vitro [78]. Since phenotype switching of melanoma cells has a 
strong impact on disease progression, novel in vitro systems are desirable [222]. Here, I 
present partial reprogramming as such a novel system to investigate the phenotype-switch. 
Of note, day-to-day investigations of changes in invasive capacity during the reprogramming 
process are of further interest to define the day of maximal invasiveness and the pace of 
phenotype switching. Examining the stability and doxycycline-dependency of the invasive 
phenotype upon abortion of transgene expression might also help understanding the 
underlying mechanisms behind the phenotype switch. 
5.4. Increased invasion potential in partially reprogrammed cells 
is not caused exclusively by transgene expression 
Partial reprogramming of multiple cell lines gave further insight into its effect on invasive 
properties. Enhanced invasion potential after partial reprogramming was not only observed in 
HCmel17 cells but also confirmed in MEFs and Hep1.6 cells. This indicates, that elevated 
invasion capacity upon partial reprogramming is not a melanoma or a cancer-associated 
phenomenon only. Interestingly, this switch towards a highly invasive status is 
reprogramming-dependent since transgene expression alone without effective 
reprogramming does not induce elevated invasion potential (i.e. Ret2 cells, Figure 13b). 
Reasons for the inability to initiate reprogramming in Ret2 cells remain undetermined. One 
possible explanation is that their high degree of genomic aberrations prevents them from 
entering reprogramming. Furthermore functionality of transgenes could be post-
transcriptionally or post-translationally modified so that Oct4, Sox and Klf4 cannot induce 
gene expression alterations efficiently. However, silencing of the complete expression 
cassette as described for transgenes in general [233] does not cause the inability to 
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reprogram Ret2 cells, as they were successfully selected using blasticidin (Table 1) and 
upon nine days of selection (day 12 after reprogramming) viable Ret2 cells were detected. 
In summary, expression of the Stemcca-blasti in four different cell lines revealed that 
induction of reprogramming and not transgene expression alone caused enhanced invasion 
capacity after 12 days. This rules out that ectopic expression of Oct4, Sox2, and Klf4 solely 
promotes malignant properties of partially reprogrammed cells, especially as previous 
studies showed that forced Oct4 expression in normal cells in vivo caused dysplasia in 
epithelial tissues [135]. 
5.5. Partially reprogrammed HCmel17 cells show heterogeneous 
expression of established invasion-related markers 
The transiently elevated invasion potential in partially reprogrammed melanoma cells can 
give insight into gene expression patterns involved in invasion-associated programs. This 
section discusses the expression signature of neural crest-related genes in the context of 
partial reprogramming. In addition, established mesenchymal markers, which are linked to 
enhanced migratory and invasive potential in development and disease, and their expression 
during reprogramming will be discussed. 
5.5.1. Partially reprogrammed HCmel17 cells do not hijack portions of 
the neural crest program to acquire invasive properties 
Since the cultivation of melanoma cells in neural crest medium has been shown to induce the 
phenotype switch in vitro [78] and expression of neural crest- associated genes results in 
higher plasticity and enhanced metastatic potential [75], I examined the expression of neural 
crest-related genes during reprogramming (Figure 14a). Gene sets were chosen in 
accordance to a study, which demonstrated that malignant melanoma cells hijack portions of 
the embryonic neural crest invasion program using a chick embryo transplant model [75]. 
Interestingly, partially reprogrammed melanoma cells appear to use a different program to 
acquire a highly invasive state since none of the neural crest-related genes shows a strong 
increase in expression after 12 days of reprogramming. However, a slight increase at day ten 
and 12 is observed for Nestin (Nes). This is in agreement with data from a study showing 
that co-expression of Nestin and Sox2 in melanoma cells correlates with disease progression 
[177]. However, the increase in Nestin upon partial reprogramming is relatively low 
(log2 [FC]=1.25) and since all other neural crest-related markers are not upregulated at 
day 12, it indicates that partially reprogrammed cells did not use modulation of the neural 
crest gene expression signature to acquire enhanced invasive potential. In accordance, 
another study demonstrated that neural crest-related gene expression signature is rather 
associated with a group of melanoma cells exhibiting low metastatic potential  [80]. Of note, 
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reprogramming is not the simple reversion of differentiation pathways and does not 
necessarily induce expression of markers, which are important during early steps of normal 
differentiation, but rather adapts other mechanisms including mesenchymal-to-epithelial 
transition (MET) [156,157,234,235]. Thus, expression of neural crest-related markers during 
the process of reprogramming is not required for HCmel17 cells to acquire pluripotency. 
However, whether or not neural crest-related genes are expressed at time points during 
reprogramming that have not been evaluated in this study (earlier than day ten, later than 
day 18) remains to be investigated. 
In summary, comparison of gene expression signatures derived from partially reprogrammed 
melanoma cells and neural crest cells revealed that neural crest signaling pathways are not 
involved in invasion-acquisition via partial reprogramming. 
5.5.2. Mesenchymal markers are not elevated in highly invasive HCmel17 
cells 
In general, partial reprogramming of melanoma cells induces two types of fate switching. On 
one hand, cells need to undergo MET-like processes to induce reprogramming, which are 
defined by expression of epithelial markers and downregulation of mesenchymal markers 
[234]. On the other hand, partial reprogramming for 12 days leads to higher invasion 
indicating upregulation of motility-supporting mesenchymal markers [236–238]. These 
contradicting processes are represented by heterogeneous expression of several different 
gene-sets at day 12 after reprogramming.  
In somatic cells of non-epithelial origin expression of particular cadherins is required for 
successful reprogramming [157,234]. Therefore, it is expected that melanoma cells also 
increase cadherins, especially Cdh1, when converted into a pluripotent state. Although 
melanocytes are derived from the non-epithelial neural crest, they express Cdh1 under 
physiological conditions in order to maintain intact connections to keratinocytes leading to 
controlled growth and limited motility. Expression of Cdh1 is also recapitulated in cell culture 
of human melanocytes [239]. However, the expression is diminished after malignant 
transformation of melanocytes into melanoma cells [240] and partially re-established at more 
advanced melanoma stages in vivo [239,241]. Consistent with this, Cdh1 is absent in 
parental HCmel17 cells but is increased at day 12, although still 250-fold lower expressed 
than in MEF-iPSCs. This is in line with the downregulation of Sparc and Snai2 (Figure 14e, 
f), which may facilitate higher Cdh1 levels since both transcription factors repress Cdh1-
expression in the context of melanoma [236,238]. In addition, Cdh2 downregulation is 
observed during partial reprogramming in line with occurring MET during reprogramming of 
somatic cells [157]. Its role in invasion-related processes suggests Cdh2 as a maker for 
invasive cells, contradicting its decreased expression in combination with elevated invasion 
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potential observed in partially reprogrammed cells (Figure 14f). Overall, the expression 
pattern of Cdh1 and Cdh2 is contrary to the observed invasion potential of partially 
reprogrammed cells. Whether or not partially reprogrammed cells at day 12 after transgene 
induction are at the stage of complete MET remains subject of investigation. 
Expression analysis of other EMT-related genes that are linked to mesenchymal phenotypes 
(Snai2, Zeb1, Zeb2 and Twist1) reveals a non-specific expression pattern showing that these 
general EMT-related markers are not essential for acquisition of invasive capacity in partially 
reprogrammed melanoma cells (Figure 14b,e). These data contradict recent studies stating 
that a change in EMT-related gene clusters in melanoma cells induces invasive properties in 
melanoma cells [77]. They describe a switch from Zeb2/Snai2-positive to Zeb1/Twist1-
positive melanoma cells when they acquire invasive properties. In contrast, in the current 
study, Zeb1 and Twist1 are not upregulated but rather downregulated in HCmel17 cells at 
day 12 of reprogramming despite their high invasion capacity (Figure 14b). It will be of 
interest whether this decrease in Twist1 and Zeb1 is caused by decreased MEK/ERK 
signaling upon partial reprogramming since Zeb1 is induced by hyperactivated RAF-signaling 
[77]. Further in-depth analysis of the phosphorylation status of mediators within the MAPK 
signaling cascade might reveal the role of its activation in gaining invasive potential. 
Snai1 and Snai2 are widely excepted to regulate EMT, trigger invasion in cancer cells and 
drive metastasis [77,242,243]. Partially reprogrammed melanoma cells exhibit these 
enhanced migratory and invasive features with increased lung extravasation ability although 
they express only moderate levels of Snai1 and Snai2 (Figure 14e). However, the 
expression of Snai1 and Snai2 correlates with MET processes accompanied by 
downregulated mesenchymal markers during reprogramming [151]. In addition, it will be of 
interest, whether exogenous Sox2 and Oct4 from the Stemcca-blasti vector suppress the 
EMT mediator Snai1 during partial reprogramming, since it was shown that Snai1 is directly 
suppressed by these pluripotency-associated genes during reprogramming of MEFs [157]. 
Snai1 is known to be absent in the majority of melanoma samples but Snai2 was shown to 
play an essential role in melanoma progression induced by EMT-like conversions of 
melanoma cells [77,236,244]. In the present study, Snai1 and Snai2 are present at moderate 
levels during the process of partial reprogramming (Ct values between 23-26 cycles, 
Suppl. Table 5) but correlate inversely with the transient increase in invasion capacity of 
partially reprogrammed cells. This is of great interest and indicates that melanoma cells can 
recruit other pathways to develop an invasive phenotype, which are not accompanied by 
increased expression of Snai2. 
Taken together, partially reprogrammed cells do not imply mesenchymal gene expression to 
gain motility indicating that increased epithelial markers do not necessarily label non-invasive 
cells as proposed by several studies [172,238] but can also correlate with invasion capacity 
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of melanoma cells. Whether this is due to correlative or causative reasons remains to be 
determined. 
The high heterogeneity regarding the expression of particular gene sets can be explained by 
different hypotheses: First, melanoma cells harbor a repertoire of different mechanisms to 
induce invasion that are each dependent on certain gene expression patterns but are 
independent from each other resulting in contradicting expression data regarding particular 
markers. 
Second, induction of reprogramming induces expression of epithelial markers and melanoma 
cells acquire enhanced invasion despite this reprogramming-induced upregulation of 
epithelial markers. It remains unclear whether partial reprogramming and acquisition of 
invasive properties are organized in a hierarchical manner so that one process dominates 
the other one regarding gene expression signatures and thus hides important regulators of 
invasion. 
 
Of note, the expression of controversially discussed melanoma stem cell markers Cd133 and 
Rank did not correlate with invasive potential of partially reprogrammed cells [63,72] 
(Suppl. Figure 4). The high invasion potential of partially reprogrammed cells did also not 
correlate to Jarid1b expression, which has been shown to be dynamically expressed and to 
label a slowly proliferating population required for continuous melanoma growth [73]. 
Assuming a true capability of these markers to label melanoma-initiating cells [63,73], this 
data implicate that underlying mechanisms behind melanoma initiation and melanoma 
progression might be distinctive. Melanoma stem cell markers might label cells with higher 
tumorigenic potential but they are not necessarily linked to higher invasion capacity and 
disease progression. Interestingly, partial reprogramming led to transiently increased Cd271 
expression (Suppl. Figure 4). Although Cd271 has been discussed as a melanoma stem cell 
marker [66,70] it was also linked to de-differentiation of melanoma cells [245]. It is likely that 
the correlative expression pattern of Cd271 and the transiently enhanced invasion potential 
of partially reprogrammed cells is rather linked to Cd271’s role in de-differentiation than to its 
melanoma stem cell-labeling properties. Taken together, the regulation of enhanced invasion 
in partially reprogrammed cells did not imply expression of melanoma stem cell markers. 
 
5.6. The invasion mode of partially reprogrammed cells is linked 
to amoeboid-like migration rather than MMP-driven proteolytic 
migration 
It is unlikely that the enhanced invasive property of partially reprogrammed cells is caused by 
proteolytic degradation of extracellular matrix. MMPs, which have been shown previously to 
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be involved in melanoma cell invasion [85,87–90] were not upregulated at day 12 after 
reprogramming (Figure 14c). In contrast, a strong downregulation of Mmp3, Mmp2 and 
Mmp14 was observed during the process of reprogramming with maximum decrease in 
completely reprogrammed HCmel17-iPCCs. Moreover, MMPs in general were absent in the 
list of genes upregulated after reprogramming for 12 days (Suppl. Table 6). These data 
indicate that proteolytic degradation is not a main mode of promoting invasion upon partial 
reprogramming. Of note, Mmps are primarily regulated by posttranslational modifications and 
not via changes in expression [246], so that microarray-derived expression data used in the 
present study leave open the possibility of enhanced Mmp-activation despite decreased 
expression. However, the vast decrease, especially of Mmp2 and Mmp14 mRNA  
(log2 [FC]≤-3), suggests a proteolysis-independent mode of action. 
 
Another invasion mode of cancer cells is the so called “amoeboid mode”, which is associated 
with a small spherical shape of cells [91,95]. Strikingly, this morphology is found in the small 
round shape of partially reprogrammed HCmel17 cells and the loss of HCmel17-
characteristic processes after partial reprogramming (inlay in Figure 12b). Also, cytoskeleton 
remodeling is among the top ten pathways that are enriched in differentially regulated genes 
upon partial reprogramming (Table 4). Thus, the expression of particular genes, known to be 
involved in the amoeboid mode of invasion [86,91,95,247], was analyzed to examine whether 
amoeboid-related invasion was associated with increased lung colonization and enhanced 
invasion capability in vitro (Suppl. Figure 5). Of note, Tesk1 and Limk2, two mediators of 
cytoskeleton remodeling, were shown to be roadblocks for reprogramming MEFs towards the 
pluripotent state and their knockdown promotes cellular reprogramming [162]. Interestingly, 
Tesk1 expression was not altered and Limk2 was even increased at day 12 of 
reprogramming (Suppl. Figure 5). Thus, downregulation of these molecules might be 
required for cytoskeleton remodeling during full reprogramming of somatic cells but the 
invasive phenotype of melanoma cells upon partial reprogramming does not involve 
downregulation of Tesk1 and Limk2 expression. However, cytoskeleton remodeling-
associated programs are activated at day 12 demonstrated by gene set enrichment analysis 
(Table 4). 
In addition, partially reprogrammed melanoma cells and highly invasive breast cancer cells 
share a subset of genes that are differentially regulated (Figure 13g, [216]). Here, the 
cytoskeleton remodeling-associated genes were concomitantly regulated (i.e. Shroom3 
[217], Atp1a1 [218], and Atp6v1c1), whereas upregulation of general mesenchymal markers 
observed in invasive breast cancer cells (i.e. Glipr-2 [220] and Fibronectin/Fn [221]), was not 
required for partially reprogrammed cells to become invasive. This is in line with unchanged 
or decreased expression of additional mesenchymal markers discussed above. 
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Table 5 Gene set enrichment analysis of processes within 
the cytoskeleton remodeling pathways 
Breast cancer cells are known to use the cytoskeleton-influencing Cofilin signaling pathway 
to respond to environmental stimuli and enhance motility [215]. Members of the Cofilin 
pathway are also described to play an essential role in other tumor types including 
melanoma [248]. Analysis of gene set enrichment within processes involved in cytoskeleton 
remodeling pathways reveals the melanoma-associated MAPK signaling pathway as the 
process with the highest enrichment in deregulated genes upon partial reprogramming and 
concomitant increase in invasion (Table 5). Interestingly, the Cofilin-pathway is integrated in 
the MAPK-signaling cascade (Suppl. Figure 6). Breast cancer cells are described to de-
regulate the Cofilin-pathway in order to permit initiation of actin polymerization, which drives 
the motility cycle and ultimately leads to acquisition of invasive properties (reviewed in [215]). 
Expression data derived from partially reprogrammed HCmel17 cells indicate deceased 
Cofilin activity due to its decreased expression (Suppl. Figure 6). In addition, Limk was 
upregulated, which inactivates Cofilin via phosphorylation. However, recent studies revealed 
that the activity of Cofilin cannot be measured appropriately by determining the expression 
level or the phosphorylation status of Cofilin due to different regulatory mechanisms, which 
are independent from each other and do not all depend on phosphorylation [249,250]. Thus, 
expression data that just describe the presence of total Cofilin, are not sufficient to predict its 
signaling activity. In addition, it was 
demonstrated that not the expression of 
single genes within the Cofilin pathway 
but rather the net outcome of Cofilin 
signaling is crucial for induction of cellular 
motility [216]. This might also explain the 
assumed contradiction of increased Limk2 
expression during partial reprogramming 
despite its role as roadblocks for 
reprogramming, which further supports 
the hypothesis, that the overall net 
outcome of the Cofilin signaling cascade 
is superior to the deregulation of single 
genes involved in this pathways [215]. 
In summary, the role of differentially 
regulated genes involved in Cofilin 
signaling indicates that this pathway might 
be involved in the complex mode of 
cellular invasion, which could not be 
explained by neural crest– or EMT– 
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related signaling changes. Direct analysis of polymerization and bundling of actin filaments 
as the net-outcome of Cofilin signaling might help to further elucidate whether Cofilin-
deregulation causes enhanced invasion upon partial reprogramming. In addition, 
experimental depletion of Cofilin in HCmel17 cells and subsequent partial reprogramming will 
uncover whether the invasion increase at day 12 depends on this actin-binding protein. 
 
Taken together, it remains to be elucidated whether this invasion-program associated with 
partial reprogramming of murine melanoma cells is also present in human melanoma cells in 
vitro and in vivo. However, this study shows that the experimental in vitro system of partial 
reprogramming can be used to identify novel processes that might be connected to invasive 
properties of melanoma cells. 
 
5.7. SNAI3 is a novel invasion-related marker for melanoma with 
potential for clinical application 
Analysis of gene expression at day 12 and 18 revealed that Carcinoembryonic antigen-
related cell adhesion molecule 1 (Ceacam1) was also among the top five genes, which were 
highly upregulated at day 12 (Figure 14d). Previous studies found that this adhesion 
molecule shows gradually increasing expression from melanocytic nevi to metastatic 
specimens and is therefore a prognostic marker for melanoma progression [251]. Moreover, 
Ceacam1 is also functionally involved in resistance against anti-melanoma therapy and 
promotes melanoma cell invasion [252]. This further indicates possible causative roles for 
genes, which expression correlates with the transient phenotype switch in HCmel17 cells 
upon partial reprogramming. Thus, I propose this in vitro model as a novel system to identify 
unknown candidate genes that are expressed in accordance to the transiently enhanced 
invasion capability and might be functionally involved in melanoma progression. 
Strikingly, Snai3 is expressed in correlation with the elevated invasion potential of melanoma 
cells when they were subjected to partial reprogramming (Figure 14e). Since this 
transcription factor has been discovered as recently as 2002, its function in carcinogenesis 
has not been investigated yet. Presence of SNAI3 was confirmed on protein level in vivo in 
subcutaneous tumors derived from partially reprogrammed cells (Figure 14g) and in lung-
infiltrating melanoma cells derived from mice intravenously injected with partially 
reprogrammed cells (Figure 14h). 
Visualization of SNAI3 in human tissues reveals that nevi are barely stained, whereas 
primary melanomas show non-homogenous staining with more prominent staining in deeper 
areas (Figure 15a). The differential expression in mouse and in human melanoma tissue 
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indicates controlled SNAI3-expression during melanomagenesis making this transcription 
factor an interesting biomarker. 
In the present study, the quantitative analysis of a tissue microarray using defined IHC 
scores reveals significantly increased SNAI3 expression in primary melanoma compared to 
nevi. Strikingly, SNAI3 expression in vivo correlates with staging of patients suffering from 
primary melanomas. SNAI3 staining significantly increases from low-risk to high-risk primary 
melanomas. These data indicate that SNAI3 rather correlates with deeper growth of primary 
melanomas than with initiation of malignant transformation of melanocytes in benign nevi. 
Data from SNAI3 visualization in human tissues are in line with increased SNAI3 expression 
in partially reprogrammed murine cells, which comprise increased invasion capability in vitro 
and in vivo (Figure 14e). Of note, it remains to be determined whether SNAI3 expression is 
required for enhanced invasion capability of partially reprogrammed cells or whether it simply 
labels invasive melanoma cells rather than being actively involved in inducing invasive 
properties. Experimental depletion of SNAI3 in parental HCmel17 cells and subsequent 
induction of partial reprogramming will uncover whether SNAI3 is required for reprogramming 
and for the highly invasive phenotype of partially reprogrammed melanoma cells. 
In melanoma, a variety of biomarkers has been identified during the last decades using high 
throughput screening (reviewed in [253] and [254]). All biomarkers identified using cell lines 
and high throughput analysis of gene expression require confirmation in independent data 
sets and verification in clinically relevant settings [253]. SNAI3, which I identified using a cell 
line-based in vitro assay, demonstrates clinical relevance by being differently expressed 
within primary tumors with prominence in invasive regions. This brings SNAI3 a step closer to 
clinical application. Importantly, in melanoma a drastic drop of five-year relative survival is 
observed between stage 0 and IV. 89 % to 95 % with localized stage I survive five years after 
diagnosis, whereas only 9 % to 19 % with distant stage IV melanoma reach this time point 
[255]. Thus, the conversion from a low-risk to a high-risk primary melanoma defines disease 
progression and this underlines the need for biomarkers, which distinguish between these 
stages of primary melanomas, i.e. SNAI3. 
In mice, SNAI3 expression was high in experimental primary melanomas but strong 
expression was not maintained in lung-infiltrating melanoma cells (Figure 14g-h), implying a 
switch of expression signature as melanoma cells metastasize. This is in agreement with 
previous studies showing the reversible adjustment of expression of other genes in 
metastasizing melanoma cells, e.g. Brn2 and pigmentation-related genes [102]. The study 
also disclosed that circulating melanoma cells show the expression pattern of highly invasive 
cells disseminating from the primary melanoma. Thus, it is of great interest whether SNAI3-
positive melanoma cells are present in the circulating of melanoma patients. This analysis 
will define whether SNAI3 also has the potential to be used as a serum biomarker. In 
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addition, paired SNAI3 expression analyses of primary melanomas and their associated 
metastases, are required in order to determine SNAI3’s potential to label invasive cells in a 
reversible manner in human as demonstrated experimentally in murine cells. 
 
In summary, I demonstrate that partial reprogramming reveals the novel biomarker SNAI3 
that correlates with tumor thickness and distinguishes between low-risk and high-risk 
melanomas. This proves that partial reprogramming of melanoma cells is a suitable in vitro 
model to identify biomarkers for melanoma progression and patient stratification.  
5.8. Exogenous expression of SNAI3 in human melanoma cells is 
not sufficient to enhance invasive properties in vitro 
Although expression of SNAI3 correlates with the transiently occurring invasive phenotype 
switch in melanoma cells upon partial reprogramming and to tumor thickness in human 
melanoma, its ectopic expression in human melanoma cells is not sufficient to enhance 
invasion capacity in vitro. 
Four melanoma cell lines and immortalized human fibroblasts were stably transduced with an 
empty control vector (pLX) or a SNAI3-encoding vector in order to examine the effect of 
ectopic SNAI3 expression on cellular functions. Interestingly, fibroblasts overexpressing 
SNAI3 displayed an elongated cell body indicating a senescence–like morphology [256] 
together with decreased proliferation so that these cells could not be cultured for more than 
one passage (Figure 16d). The fact that cells do not proliferate but can be cultured for longer 
than 14 days without passaging indicates senescence rather than increased cell death upon 
SNAI3 expression. However, whether senescence-associated mechanisms are truly 
activated upon SNAI3-overexpression in fibroblasts remains to be determined. Of note, 
inhibited proliferation upon SNAI3-overexpression is not caused by blasticidin selection since 
pLX-transduced cells were cultured under the exact same selection-condition and they kept 
their normal morphology and could be cultured under normal conditions for at last seven 
passages (data not shown). This indicates that SNAI3 has an effect on proliferation or 
senescence of fibroblasts, whereas in contrast, melanoma cell lines overexpressing SNAI3 
did not discontinue to proliferate and could be cultured for at least seven passages after 
blasticidin selection. In addition, in melanoma cell lines, SNAI3-overexpression does not 
induce morphological changes comparable to senescence-triggered elongation of the cell 
body showing that the effect of SNAI3 regarding senescence differs when it is overexpressed 
in normal fibroblasts or in melanoma cells. This difference might be caused by the fact that 
fibroblasts are non-malignant cells and SNAI3 expression only induces senescence-like 
morphology in normal cells, or that the effect is lineage dependent. SNAI3 overexpression in 
normal melanocytes will elucidate the dependence of morphological alterations on the 
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melanocytic lineage. This is technically challenging since normal human melanocytes are 
difficult to transduce and thus, fibroblasts were used as non-malignant control cells in this 
study. 
Although morphology is not affected by SNAI3 overexpression, proliferation was slightly 
decreased to 80 % in two out of the three analyzed melanoma cell lines (Figure 16e). 
However, it remains to be investigated whether this change of proliferation in SNAI3 
expressing melanoma cells is biologically relevant since the maximum decrease was limited 
to 20 %. Interestingly, SNAI3 overexpression in melanoma cells does not enhance migration 
through defined pores or invasion through a basal membrane equivalent in vitro using 
chemotactic attraction with FCS. The migration and invasion capacity of Mewo and SKmel30 
cells were not affected by SNAI3 expression and the trend of increased migration and 
invasion in A375 cells could be explained by biological variance indicated by high standard 
deviation for pLX-transduced control cells (Figure 16f-g). Invasion and migration are 
dependent on chemotactic stimuli and it has been described that different chemoattractants 
result in different outcomes [257,258]. Whether different starving conditions including glucose 
depletion affect the invasion capacities of human melanoma cells in vitro needs to be further 
investigated. 
In general, the overexpression of a single gene might not lead to functional changes since 
the acquisition of migratory and invasive capacities is a complex progress and can be 
induced by a variety of different molecular mechanisms. Thus, the inability of SNAI3 
overexpression to induce enhanced invasion capacity in vitro does not prove that it is 
dispensable for invasion in human melanoma cells. It remains to be investigated whether 
other factors might act synergistically with SNAI3 in order to promote invasive programs. 
In summary, SNAI3 overexpression in human melanoma cells is not sufficient to enhance 
migratory or invasive properties in vitro. However, the correlation of SNAI3 expression in 
human melanoma samples to disease progression supports the high clinical relevance as a 
biomarker, which distinguishes between low-risk and high-risk primary melanomas. 
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6. Conclusion 
This study was set out to dissect the reprogramming process of murine melanoma cells on 
their route to pluripotency in order to investigate the role of directed de-differentiation on 
melanoma cells’ function. It revealed that reprogramming is a time-dependent and 
reproducible process in murine HCmel17 melanoma cells. Furthermore, it discovered that 
partial reprogramming induces a transiently occurring phenotype switch of melanoma cells, 
which describes the conversion of highly proliferative and less invasive to less proliferative 
and highly invasive cells. This study further aimed to identify novel markers, which correlate 
with the metastatic potential of melanoma cells. These markers are of great importance 
because of the extremely high increase of mortality once a melanoma has metastasized. 
Using the model of partial reprogramming, I identified SNAI3 as a novel invasion-related 
marker that correlates with tumor thickness and distinguishes between low-risk and high-risk 
melanomas. 
 
In summary, two main conclusions are emphasized. First, neural crest-related gene 
expression, which has been previously shown to be heavily involved in enhanced invasion 
capacity of melanoma cells using different in vitro models [75,259], was not recruited during 
partial reprogramming. This is in agreement with another study showing that expression of 
neural crest-related genes is not increased in highly invasive human melanoma cells [80]. 
Therefore, invasive properties might be promoted by independent programs in melanoma 
cells, which further highlights their tremendous plasticity. Taken together, these results 
underline the need for careful interpretation of artificial in vitro systems since they might 
mimic biological phenomenons but do not necessarily provide insight into the underlying 
mechanisms that are recruited in vivo. This study demonstrates that different in vitro assays 
can show identical biological outcomes (enhanced invasion) without mediating it through the 
same molecular routes (neural crest-dependent vs. neural crest-independent pathways). 
Whether or not one or more of these assays give physiologically relevant insights into gene 
expression changes remains subject of investigation. 
 
The second major conclusion of this study is that the analysis of primary tumors and 
metastases, in respect to biomarkers that label invasive melanoma cells, is of great 
importance. Studies often compare gene expression between primary tumors and 
metastases to identify targets, which are more strongly expressed in metastases. Using 
these genes to find molecular mechanisms that promote disease progression and 
metastases implies a major challenge. Melanoma cells possess the ability to alter their 
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proliferation and invasion capacity in response to environmental signals [97]. Most likely, a 
reversible phenotype switch enables melanoma cells to disseminate from the primary tumor 
and establish metastases at secondary sites, which exhibit the heterogeneity of the primary 
tumor [96,102]. Thus, highly invasive melanoma cells are most probably present on the 
invasive border of primary tumors and in the circulation to home to distant organs. Within the 
established metastasis only a minority of cells are expected to be highly invasive, because at 
secondary tumor sites, proliferation is superior to invasive properties in order to establish a 
novel melanoma-metastasis. This has been elegantly shown by a study proving the 
reversible expression of differentiation/proliferation- associated and invasion-associated 
genes when melanoma cells become metastatic [102]. Strikingly, the expression of SNAI3, 
which I identified as a novel invasion-associated marker, distinguishes between low-risk and 
high-risk melanomas in patients. This increased expression in primary tumors with high risk 
to metastasize indicates a link between SNAI3 expression and invasive potential of 
melanoma cells. In vitro, partially reprogrammed murine melanoma cells strongly expressed 
SNAI3 in tumors that formed after subcutaneous injections, but only few melanoma cells 
were SNAI3-positive in experimental lung metastases. This indicates a possible switch of 
SNAI3 expression after dissemination from primary tumors. However, this has to be 
thoroughly investigated by SNAI3 expression analysis in human melanoma metastases. 
 
In summary, this study offers novel insight into melanoma cell reprogramming and the role of 
directed de-differentiation on invasive capacity of melanoma cells. It contributes to our 
understanding of the concept of melanoma phenotype switching by establishing a novel in 
vitro system. Moreover, SNAI3 was identified as a novel invasion-related marker with 
potential for clinical application as it allows to distinguish between human melanomas with 
low and high risk to metastasize. 
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